

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number  
**WO 03/051869 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 409/12**,  
471/04, 489/04, A61K 31/445, 31/44

DK-2500 Valby (DK). **BANG NØRGAARD, Morten**  
[DK/DK]; Buddingevej 130A, DK-2800 Lyngby (DK).

(21) International Application Number: PCT/DK02/00858

(22) International Filing Date:  
16 December 2002 (16.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA200101916 19 December 2001 (19.12.2001) DK  
60/341,905 19 December 2001 (19.12.2001) US

(71) Applicant (for all designated States except US): **H. LUNDBECK A/S** [DK/DK]; Ottiliavej 9, DK-2500 Valby-Copenhagen (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KEHLER, Jan** [DK/DK]; Nymøllevej 28, DK-2800 Kgs. Lyngby (DK). **POULSEN, Anders** [DK/DK]; Drejøgade 26F, 101, DK-2100 København Ø (DK). **BJØRNHOLM, Berith** [DK/DK]; Højlandsvej 12, DK-3500 Værløse (DK). **KROLL, Friedrich** [DE/DK]; Kirstinedalsvej 4, 3th,

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES



(57) Abstract: The present invention relates to novel compounds of formula I wherein the variable groups are as defined in the claims or a pharmaceutically acceptable acid addition salt thereof. The compounds of the invention are NK2 antagonists.

WO 03/051869 A1

### 3,4-dihydro-1H-isoquinolin-2-yl-derivatives

#### Field of the Invention

5 The compounds of the present invention belong to a novel class of 3,4-dihydro-1H-isoquinolin-2-yl-derivatives having affinity for the neurokinin 2 (NK2) receptor. The compounds are NK2-antagonists and are useful in the treatment of those diseases where an NK2-receptor is implicated like asthma and a CNS-disease. These novel 3,4-dihydro-1H-isoquinolin-2-yl-derivatives are capable of penetrating the blood brain barrier and  
10 therefore useful in treating a variety of CNS diseases.

#### Background of the invention

Three tachykinins, Substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) are  
15 widely distributed throughout the peripheral and central nervous systems. The biological effects of these neuropeptides are carried out via binding to their preferred receptors, NK1, NK2 and NK3 (Guard, S. and Watson, S. P. *Neurochem. Int.* **1991**, *18*, 149). Substance P displays highest affinity for the NK1 receptors, whereas NKA and NKB bind preferentially to NK2 and NK3 receptors, respectively. The selectivities of the endogenous ligands for  
20 their respective receptors are not absolute (reviewed in Regoli, D. et al. *Pharmacol. Rev.* **1994**, *46*, No. 4, 551 plus Bremer, A. A. et al. *Eur J Pharmacol* **2001**, *423*, 143). The three receptor subtypes belong to the G-protein-coupled receptor super family and have been cloned in various species including mice, rats and humans (Giardina, G. A. M. et al. *Drugs of the Future* **1997**, *22*, 1235 and references herein).

25

Activation of the tachykinin receptors influences a broad array of biological actions, including pain transmission, vasodilation, smooth muscle contraction, secretion of saliva, bronchoconstriction, activation of the immune system (inflammatory pain), neurogenic inflammation and neurotransmission (Patacchini, R. et Maggi, C.A. *Eur J Pharmacol.* **2001**,  
30 429, 13; Longmore, J. et al. *Can J Physiol Pharmacol* **1997**, *75*, 612; Giardina, G. A. M. et al. *Drugs of the Future* **1997**, *22*, 1235 and references herein).


Expression of NK2 receptors in human is somewhat controversial. The receptor is generally expressed in low amounts in CNS, and autoradiographic studies have failed to show NK2 receptors in the human brain. A recent reverse transcription-polymerase chain reaction (RT-PCR) study, however, has revealed a detectable expression of NK2 receptor mRNA in various human brain regions including caudate nucleus, putamen, hippocampus, substantia nigra and cerebral cortex (Bensaid, M et al. *Neurosci Lett* **2001**, 303, 25).

Up-regulation of the preprotachykinin (PPT) genes and mRNAs for the neurokinin receptors occurs both in animal models of disease (Fischer, A. et al. *J Clin Invest* **1996**, 98, 2284) and in human diseases, such as asthma (Adcock, I. M. et al. *J Mol Endocrino* **1993**, 11, 1).

NK antagonists have been and are under investigations for the treatment of a vast amount of both CNS related and peripheral diseases. A number of pre-clinical studies have been performed to assess the involvement of NK1 and NK2 receptors mediation and modulation of diseases related to anxiety and/or depression (Griebel, G. Et al. *Psychopharmacology*, **2001**, 158, 241; Walsh, D. M. et al. *Psychopharmacology* **1995**, 121, 186; Rupniak, N. M. et al. *Neuropharmacology* **2000**, 39, 1413; Rupniak, N. M. et Kramer, M.S. *TiPS* **1999**, 20, 485;; Giardina, G. A. M. et al. *Drugs of the Future* **1997**, 22, 1235, and references in these).

These studies indicate that NK2 antagonists will be useful in treating or preventing a variety of brain disorders including depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis, and Huntington's disease as well as Parkinson's disease, adjustment disorders, pain, emesis, migraine, epilepsy, obesity, asthma and cerebrovascular disease. However, peripheral diseases such as inflammation, inflammatory bowel disease, hypertension, arthritis, cardiovascular diseases, neuritis, neuralgia, urticaria, incontinence, gastrointestinal diseases, influenza, allergy, pulmonary allergy and carcinoma / tumoral growth may also be addressed by NK2 antagonists.

US 3,994,891 discloses tetrahydroisoquinolines of the general formula



wherein R is hydrogen or methyl, and G is NH or CH<sub>2</sub>. The dihydroxy compounds are described as effective vasodilators, whereas the dimethoxy compounds are intermediates in the manufacture of the dihydroxy compounds.

5

Hence, there is a desire for novel compounds that are antagonists at the NK2 receptor.


### Summary of the Invention

10 The objective of the present invention is to provide compounds that are antagonists at the NK2 receptor.

A further objective of the present invention is to provide compounds with such activities which have improved solubility, metabolic stability and/or bioavailability compared to prior art compounds.

15

Accordingly, the present invention relates to novel compounds of formula I



wherein

$R^1$  is a group  $R^{11}CO-$ ,  $R^{11}CS-$ ,  $R^{11}SO_2-$ ,  $R^{11}OCO-$ ,  $R^{11}SCO-$  or  $R^{11}CO-CR^{12}R^{13}-$  wherein  $R^{11}$  is  $C_{1-12}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, aryl, aryl- $C_{1-6}$ -alkyl, heteroaryl, heteroaryl- $C_{1-6}$ -alkyl, tetrahydropyranyl, 1,2,3,4-tetrahydronaphthalenyl, or 4H-benzo[1,3]dioxinyl optionally substituted with halogen wherein each of said  $C_{1-6}$ -alkyl, aryl, heteroaryl and  $C_{3-8}$ -cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy, aryl- $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylsulfanyl, aryl and aryloxy wherein said aryl and aryloxy independently are unsubstituted or substituted with one or more halogen, and  $R^{12}$  and  $R^{13}$  independently are hydrogen or  $C_{1-6}$ -alkyl; or  $R^1$  is a group  $R^{14}R^{15}NCO-$ ,  $R^{14}R^{15}NCS-$ , wherein  $R^{14}$  and  $R^{15}$  are independently hydrogen,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, aryl or aryl- $C_{1-6}$ -alkyl, wherein each of said  $C_{1-6}$ -alkyl, aryl and  $C_{3-8}$ -cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen,  $C_{1-6}$ -alkyl and  $C_{1-6}$ -alkoxy, or  $R^{14}$  and  $R^{15}$  together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group;

$R^2$  is selected from hydrogen, trifluoromethyl and  $C_{1-6}$ -alkyl;

$R^3$ - $R^6$ ,  $R^{7a}$ ,  $R^{7b}$ ,  $R^{8a}$  and  $R^{8b}$  are independently selected from hydrogen, halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, amino,  $C_{1-6}$ -alkylamino, di- $(C_{1-6}$ -alkyl)amino,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di- $(C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and  $C_{1-6}$ -alkylsulfonyl;

m is 2-6;

$R^9$  is benzyl, benzoyl, 2,3-dihydrobenzofuranyl or mono- or bicyclic aryl or heteroaryl wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, amino,  $C_{1-6}$ -alkylamino, di- $(C_{1-6}$ -alkyl)amino,


C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl;

5 Q is C, N or CR<sup>10</sup>;

wherein R<sup>10</sup> is selected from hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino, C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl)amino, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-  
 10 (C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl, a group -NR<sup>30</sup>COR<sup>31</sup> wherein R<sup>30</sup> is hydrogen or C<sub>1-6</sub>-alkyl and R<sup>31</sup> is C<sub>1-6</sub>-alkyl, a group -COOR<sup>16</sup> wherein R<sup>16</sup> is hydrogen or C<sub>1-6</sub>-alkyl, or a group -CONR<sup>17</sup>R<sup>18</sup> wherein R<sup>17</sup> and R<sup>18</sup> independently are selected from hydrogen and C<sub>1-6</sub>-alkyl or R<sup>17</sup> and R<sup>18</sup> together with the nitrogen to which they are attached  
 15 form a piperidinyl, piperazinyl or morpholinyl, wherein said piperidinyl, piperazinyl and morpholinyl is unsubstituted or substituted with a C<sub>1-6</sub>-alkyl;

or R<sup>9</sup> and R<sup>10</sup> together with the carbon to which they are attached form a cyclic structure selected from the group comprising:

20



25 wherein Q' is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure; and

X, Y, and Z are independently chosen from O;  $\text{NR}^{19}$ ;  $\text{CR}^{23}\text{R}^{24}$ ;  $\text{S(O)}_n$  and a bond; wherein  $\text{R}^{19}$  is selected from hydrogen,  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{2-6}$ -alkenyl,  $\text{C}_{2-6}$ -alkynyl,  $\text{C}_{3-8}$ -cycloalkyl,  $\text{C}_{3-8}$ -cycloalkyl- $\text{C}_{1-6}$ -alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or  $\text{R}^{19}$  is a group  $\text{R}^{20}\text{SO}_2$ -,  $\text{R}^{20}\text{OCO}$ - or  $\text{R}^{20}\text{SCO}$ - wherein  $\text{R}^{20}$  is  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{2-6}$ -alkenyl,  $\text{C}_{2-6}$ -alkynyl,  $\text{C}_{3-8}$ -cycloalkyl,  $\text{C}_{3-8}$ -cycloalkyl- $\text{C}_{1-6}$ -alkyl or aryl, or  $\text{R}^{19}$  is a group  $\text{R}^{21}\text{R}^{22}\text{NCO}$ - or  $\text{R}^{21}\text{R}^{22}\text{NCS}$ -, wherein  $\text{R}^{21}$  and  $\text{R}^{22}$  are independently hydrogen,  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{2-6}$ -alkenyl,  $\text{C}_{2-6}$ -alkynyl,  $\text{C}_{3-8}$ -cycloalkyl,  $\text{C}_{3-8}$ -cycloalkyl- $\text{C}_{1-6}$ -alkyl, or aryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from  $\text{C}_{1-6}$ -alkyl or halogen; or  $\text{R}^{21}$  and  $\text{R}^{22}$  together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group;  $\text{R}^{23}$  and  $\text{R}^{24}$  are independently selected from hydrogen, halogen, cyano, nitro,  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{2-6}$ -alkenyl,  $\text{C}_{2-6}$ -alkynyl,  $\text{C}_{3-8}$ -cycloalkyl,  $\text{C}_{3-8}$ -cycloalkyl- $\text{C}_{1-6}$ -alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from  $\text{C}_{1-6}$ -alkyl or halogen, amino,  $\text{C}_{1-6}$ -alkylamino, a group  $\text{NR}^{25}\text{R}^{26}$  wherein  $\text{R}^{25}$  and  $\text{R}^{26}$  are independently selected from  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $\text{C}_{1-6}$ -alkylaminocarbonyl, di- $(\text{C}_{1-6}$ -alkyl)aminocarbonyl,  $\text{C}_{1-6}$ -alkoxy,  $\text{C}_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and  $\text{C}_{1-6}$ -alkylsulfonyl or  $\text{R}^{25}$  and  $\text{R}^{26}$  together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, or  $\text{R}^{23}$  and  $\text{R}^{24}$  together is oxo; and n is 0, 1 or 2; provided that no more than one of X, Y and Z may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time be selected from O and S; and

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{A}^3$  and  $\text{A}^4$  are independently selected from N and  $\text{CR}^{27}$  wherein  $\text{R}^{27}$  is hydrogen, halogen, cyano, nitro,  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{2-6}$ -alkenyl,  $\text{C}_{2-6}$ -alkynyl,  $\text{C}_{3-8}$ -cycloalkyl,  $\text{C}_{3-8}$ -cycloalkyl- $\text{C}_{1-6}$ -alkyl,  $\text{C}_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $\text{C}_{1-6}$ -alkylaminocarbonyl, di- $(\text{C}_{1-6}$ -alkyl)aminocarbonyl,  $\text{C}_{1-6}$ -alkoxy,  $\text{C}_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl  $\text{C}_{1-6}$ -alkylsulfonyl amino or a group  $\text{NR}^{28}\text{R}^{29}$  wherein  $\text{R}^{28}$  and  $\text{R}^{29}$  are independently selected from hydrogen and  $\text{C}_{1-6}$ -alkyl or  $\text{R}^{28}$  and  $\text{R}^{29}$  together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group; provided that only one of  $\text{A}^1$ ,  $\text{A}^2$ ,  $\text{A}^3$  and  $\text{A}^4$  may be N; and

the dotted line emanating from Q is a bond when Q is C, and no bond when Q is  $\text{CR}^{10}$  or N;


or a pharmaceutically acceptable acid addition salt thereof.

### Detailed Description of the Invention

- 5 The C<sub>1-12</sub>-alkyl groups defined for R<sup>11</sup> are preferably selected from C<sub>1-10</sub>-alkyl, more preferred C<sub>1-8</sub>-alkyl, and most preferred C<sub>3-8</sub>-alkyl.

In one embodiment, the present invention relates to such compounds wherein Q is CR<sup>10</sup>, and R<sup>9</sup> and R<sup>10</sup> together with the carbon to which they are attached form a bicyclic structure:

10



1),

wherein Q' is the carbon shared with the piperidine ring, so that said bicyclic structure together with said piperidine ring form a spiro structure; and

- 15 X, Y and Z are independently chosen from O; NR<sup>19</sup>; CR<sup>23</sup>R<sup>24</sup> and S(O)<sub>n</sub> wherein R<sup>19</sup> is selected from hydrogen, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or R<sup>19</sup> is a group R<sup>20</sup>SO<sub>2</sub>-, R<sup>20</sup>OCO- or R<sup>20</sup>SCO- wherein R<sup>20</sup> is C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl or aryl, or R<sup>19</sup> is a group
- 20 R<sup>21</sup>R<sup>22</sup>NCO-, R<sup>21</sup>R<sup>22</sup>NCS-, wherein R<sup>21</sup> and R<sup>22</sup> are independently hydrogen, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl or aryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C<sub>1-6</sub>-alkyl or halogen; or R<sup>21</sup> and R<sup>22</sup> together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group; R<sup>23</sup> and R<sup>24</sup> are independently selected
- 25 from hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C<sub>1-6</sub>-alkyl or halogen, amino, C<sub>1-6</sub>-alkylamino, a group NR<sup>25</sup>R<sup>26</sup> wherein R<sup>25</sup> and R<sup>26</sup> are independently selected from C<sub>1-6</sub>-alkyl or R<sup>25</sup> and R<sup>26</sup> together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl,
- 30 perhydroazepinyl or morpholinyl group, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl,



C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl, and C<sub>1-6</sub>-alkylsulfonyl or R<sup>23</sup> and R<sup>24</sup> together is oxo; and n is 0, 1 or 2; and a bond; provided that no more than one of X, Y and Z may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time  
 5 be selected from O and S; and

A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup> are independently selected from N and CR<sup>27</sup> wherein R<sup>27</sup> is hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino, a group NR<sup>28</sup>R<sup>29</sup> wherein R<sup>28</sup> and R<sup>29</sup> are independently selected from  
 10 hydrogen and C<sub>1-6</sub>-alkyl or R<sup>28</sup> and R<sup>29</sup> together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl or C<sub>1-6</sub>-alkylsulfonyl; provided that only one of A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup>  
 15 may be N.

In a preferred embodiment, the present invention relates to such compounds wherein X, Y and Z are selected from one of the combinations: X is oxygen, Y is a bond and Z is CR<sup>23</sup>R<sup>24</sup>; X is CR<sup>23</sup>R<sup>24</sup>, Y is a bond and Z is oxygen; X is NR<sup>19</sup>, Y is a bond and Z is  
 20 CR<sup>23</sup>R<sup>24</sup>; X is CR<sup>23</sup>R<sup>24</sup>, Y is a bond and Z is NR<sup>19</sup>; X is CO, Y is a bond and Z is NR<sup>19</sup>; X is SO<sub>2</sub>, Y is a bond and Z is NR<sup>19</sup>; X is SO, Y is a bond and Z is NR<sup>19</sup>; X is CR<sup>23</sup>R<sup>24</sup>, Y is a bond and Z is S; X is CR<sup>23</sup>R<sup>24</sup>, Y is a bond and Z is SO; X is CR<sup>23</sup>R<sup>24</sup>, Y is a bond and Z is SO<sub>2</sub>; wherein R<sup>19</sup> is hydrogen, acetyl or methylsulfonyl and R<sup>23</sup> and R<sup>24</sup> are independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl.

25


In another preferred embodiment, the present invention relates to such compounds wherein -X-Y-Z- together form a group selected from: -O-CR<sup>23</sup>R<sup>24</sup>-, -CR<sup>23</sup>R<sup>24</sup>-O-, -NR<sup>19</sup>-CR<sup>23</sup>R<sup>24</sup>-, -CR<sup>23</sup>R<sup>24</sup>-NR<sup>19</sup>-, -CO-NR<sup>19</sup>-, -SO<sub>2</sub>-NR<sup>19</sup>-, -SO-NR<sup>19</sup>-, -CR<sup>23</sup>R<sup>24</sup>-S-, -CR<sup>23</sup>R<sup>24</sup>-SO-, -CR<sup>23</sup>R<sup>24</sup>-SO<sub>2</sub>-; wherein R<sup>19</sup> is hydrogen, acetyl or methylsulfonyl and R<sup>23</sup> and R<sup>24</sup> are  
 30 independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl.

In another preferred embodiment, the present invention relates to such compounds wherein A<sup>3</sup> is N or CR<sup>27</sup> wherein R<sup>27</sup> is halogen, cyano, nitro, a group NR<sup>28</sup>R<sup>29</sup> wherein R<sup>28</sup> and R<sup>29</sup>

are independently selected from hydrogen and C<sub>1-6</sub>-alkyl or R<sup>28</sup> and R<sup>29</sup> together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl or C<sub>1-6</sub>-alkylsulfonyl.


In another preferred embodiment, the present invention relates to such compounds wherein A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup> are independently selected from CR<sup>27</sup> wherein R<sup>27</sup> is as defined above.

In a more preferred embodiment, the present invention relates to such compounds wherein bicyclic structure described above is selected from the group comprising:



wherein R<sup>19'</sup> is acetyl or methylsulfonyl, R<sup>23'</sup> is hydrogen or methyl, R<sup>27'</sup> is hydrogen or fluoro, R<sup>27''</sup> is hydrogen, fluoro, methyl or isopropyl, R<sup>27'''</sup> is hydrogen, fluoro or trifluoromethyl.

In another embodiment, the present invention relates to such compounds wherein R<sup>9</sup> and R<sup>10</sup> together with the carbon to which they are attached form a cyclic structure selected from the group comprising:



wherein Q' is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure

In yet another embodiment, the present invention relates to such compounds wherein R<sup>9</sup> is  
5 benzyl, benzoyl, 2,3-dihydrobenzofuran-7-yl or mono- or bicyclic aryl or heteroaryl  
wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more  
substituents selected from halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl,  
C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino, C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl)amino,  
C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl,  
10 C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and  
trifluoromethylsulfonyl.

In yet another embodiment, the present invention relates to such compounds wherein R<sup>9</sup> is  
2,3-dihydrobenzofuran-7-yl, benzyl or benzoyl wherein said benzyl or benzoyl is  
15 unsubstituted or substituted with one or more halogens in the phenyl groups, or R<sup>9</sup> is mono-  
or bicyclic aryl or heteroaryl selected from the group comprising phenyl, indolyl, pyridyl,  
thiophenyl and benzisoxazolyl, wherein each aryl or heteroaryl optionally is substituted with  
one or more substituents selected from halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl,  
C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino, C<sub>1-6</sub>-alkylamino, di-  
20 (C<sub>1-6</sub>-alkyl)amino, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-  
(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl,  
difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.

In a preferred embodiment, the present invention relates to such compounds wherein said  
25 mono- or bicyclic aryl or heteroaryl is selected from the group comprising phenyl, indol-  
3-yl and benzisoxazol-3-yl wherein said phenyl, indol-3-yl or benzisoxazol-3-yl optionally  
is substituted with one or more substituents selected from halogen, cyano, nitro, C<sub>1-6</sub>-alkyl,  
C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino,  
C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl)amino, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl,  
30 C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio,  
hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.

In an even more preferred embodiment, the present invention relates to such compounds wherein said optional substituents are selected from the group comprising halogen, phenyl and methyl.

5 In yet another embodiment, the present invention relates to such compounds wherein Q is  $CR^{10}$  wherein  $R^{10}$  is selected from hydrogen,  $C_{1-6}$ -alkylcarbonyl, hydroxy, a group  $-NR^{30}COR^{31}$  wherein  $R^{30}$  is hydrogen or  $C_{1-6}$ -alkyl and  $R^{31}$  is  $C_{1-6}$ -alkyl, a group  $-COOR^{16}$  wherein  $R^{16}$  is  $C_{1-6}$ -alkyl, or a group  $-CONR^{17}R^{18}$  wherein  $R^{17}$  and  $R^{18}$  together with the nitrogen to which they are attached form a piperidiny, piperaziny or morpholiny, wherein  
10 said piperidiny, piperaziny and morpholiny are unsubstituted or substituted with a  $C_{1-6}$ -alkyl.

In a preferred embodiment, the present invention relates to such compounds wherein  $R^{10}$  is selected from hydrogen, acetyl, hydroxy, a group  $-NR^{30}COR^{31}$  wherein  $R^{30}$  is hydrogen and  
15  $R^{31}$  is methyl, a group  $-COOR^{16}$  wherein  $R^{16}$  is ethyl, or a group  $-CONR^{17}R^{18}$  wherein  $R^{17}$  and  $R^{18}$  together with the nitrogen to which they are attached form a piperidiny or a 4-methylpiperaziny.

In another preferred embodiment, the present invention relates to such compounds wherein  
20 m is 2,3 or 4, more preferred m is 2.

In yet another embodiment, the present invention relates to such compounds wherein  $R^1$  is a group  $R^{11}CO-$ ,  $R^{11}OCO-$  wherein  $R^{11}$  is  $C_{3-6}$ -alkyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, phenyl, phenyl- $C_{1-6}$ -alkyl, pyridyl, furanyl, benzo[1,2,5]oxadiazolyl, quinoxaliny, benzo[b]thiophenyl or naphthalenyl wherein each of said  $C_{3-6}$ -alkyl, phenyl, pyridyl and furanyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy, phenyl and phenoxy wherein said phenyl and phenoxy independently are unsubstituted or substituted with one halogen; or  $R^1$  is a group  $R^{14}R^{15}NCO-$ , wherein  $R^{14}$  and  $R^{15}$  are independently  
25 hydrogen,  $C_{1-6}$ -alkyl, aryl, or aryl- $C_{1-6}$ -alkyl, wherein each of said  $C_{1-6}$ -alkyl and aryl groups independently are unsubstituted or substituted with one substituent selected from the group comprising halogen and  $C_{1-6}$ -alkoxy.  
30

In yet another embodiment, the present invention relates to such compounds wherein R<sup>2</sup> is hydrogen.

5 In yet another embodiment, the present invention relates to such compounds wherein R<sup>3</sup> is hydrogen.

In yet another embodiment, the present invention relates to such compounds wherein R<sup>4</sup> is hydrogen or methoxy.

10 In yet another embodiment, the present invention relates to such compounds wherein R<sup>5</sup> is hydrogen or methoxy.

In yet another embodiment, the present invention relates to such compounds wherein R<sup>6</sup> is hydrogen.

15 In yet another embodiment, the present invention relates to such compounds wherein R<sup>7a</sup> and R<sup>7b</sup> is hydrogen.

In yet another embodiment, the present invention relates to such compounds wherein R<sup>8a</sup> and R<sup>8b</sup> is hydrogen.

20

Preferred compounds of the invention are compounds number 1-209 as disclosed in the experimental section as well as the compounds in the following list:

25 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,  
1-cyclopentyl-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,  
1-cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-  
30 5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,  
1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,

- 1-cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone,
- 1-(4-fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone,
- 5 *N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-phenylpiperidin-4-yl]acetamide,
- 10 *N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-phenylpiperidin-4-yl]acetamide,
- 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,
- 15 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,
- 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro 1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,
- 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,
- 20 1-cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 1-(4-fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 25 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,
- 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,
- 1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone,
- 30 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone,

- 1-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone,
- 1-cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 5 1-(1-{2-[4-(5-fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,
- 1-cyclopentyl-1-(1-{2-[4-(5-fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,
- 1-cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,
- 10 3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,
- 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,
- 1-cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,
- 15 1-(4-fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,
- N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- 20 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-phenylpiperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-phenylpiperidin-4-yl]acetamide,
- 25 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl}methanone,
- 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl}methanone,
- 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro 1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl}methanone,
- 30 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl}methanone,

- 1-cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,  
1-(4-fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,  
5 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,  
1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,  
1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-methanone,  
10 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,  
1-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-methanone,  
15 1-cyclopentyl-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,  
1-(1-{2-[4-(5-fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,  
1-cyclopentyl-1-(1-{2-[4-(5-fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
20 1-cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
25 1-cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(4-fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
*N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,  
30 *N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,



- N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- 5 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,
- 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,
- 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro *1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,
- 10 ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,
- 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-*1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,
- 1-cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 15 1-(4-fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,
- 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,
- 20 1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-methanone,
- 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 25 1-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-methanone,
- 1-cyclopentyl-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,
- 30 1-cyclopentyl-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,

- 1-cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
5 1-cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
1-(4-fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]ethyl}-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
*N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-  
10 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,  
*N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,  
*N*-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,  
15 *N*-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,  
1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-  
20 5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro *1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-*1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
25 1-cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
1-(4-fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone,  
1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-  
30 *1H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,  
1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,

- 1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone,  
1-(4-fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
5 1-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone, and  
1-cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone.
- 10 The compounds of the invention are NK<sub>2</sub> receptors antagonists having a human NK<sub>2</sub> binding affinity (IC<sub>50</sub>) of 5 μM or less, typically of 1 μM or less, preferably of 200 nM or less, more preferred of 50 nM or less and most preferred of 10 nM or less.

Accordingly, the compounds of the invention are considered useful in treating a variety of  
15 CNS diseases such as depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis and Huntington's disease as well as Parkinson's dementia, adjustment disorders, pain, emesis, migraine, epilepsy, obesity and  
20 cerebrovascular disease.

In particular, the compounds of the invention are considered useful in the treatment of depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic  
25 stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder and psychosis.

Thus, in another aspect, the present invention provides a pharmaceutical composition comprising at least one compound of formula I as defined above or a pharmaceutically  
30 acceptable acid addition salt thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.

In a further aspect, the present invention provides the use of a compound of formula I as defined above or an acid addition salt thereof for the manufacture of a pharmaceutical preparation for the treatment of the above mentioned disorders.

- 5 The compounds of the general formula I may exist as optical isomers thereof and such optical isomers are also embraced by the invention. Throughout the specification and claims, reference to specific compounds refers to the racemates unless otherwise indicated.

The term C<sub>1-6</sub>-alkyl refers to a branched or unbranched alkyl group having from one to six  
10 carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, and 2-methyl-1-propyl. The terms C<sub>1-8</sub>-alkyl, C<sub>1-10</sub>-alkyl and C<sub>1-12</sub>-alkyl, respectively, refer similarly to branched or unbranched alkyl group having from one to eight, ten or twelve carbon atoms inclusive, respectively.

- 15 Similarly, C<sub>2-6</sub>-alkenyl and C<sub>2-6</sub>-alkynyl, respectively, designate such groups having from two to six carbon atoms, including one double bond and one triple bond, respectively, such as ethenyl, propenyl, butenyl, ethynyl, propynyl and butynyl.

The term C<sub>3-8</sub>-cycloalkyl designates a monocyclic or bicyclic carbocycle having three to  
20 eight C-atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, etc.

Halogen means fluoro, chloro, bromo or iodo.

- As used herein, the term acyl refers to a formyl, C<sub>1-6</sub>-alkylcarbonyl, arylcarbonyl, aryl-  
25 C<sub>1-6</sub>-alkylcarbonyl, C<sub>3-8</sub>-cycloalkylcarbonyl or a C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl-carbonyl group, and the term thioacyl is the corresponding acyl group, in which the carbonyl group is replaced with a thiocarbonyl group.

- The terms C<sub>1-6</sub>-alkoxy, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkylsulfonyl, C<sub>1-6</sub>-alkylamino,  
30 C<sub>1-6</sub>-alkylcarbonyl, and the like, designate such groups in which the C<sub>1-6</sub>-alkyl and the C<sub>3-8</sub>-cycloalkyl group are as defined above.

The term aryl refers to a carbocyclic aromatic group, such as phenyl or naphthyl, in particular phenyl.

The term heteroaryl refers to 5-membered monocyclic rings such as 1*H*-tetrazolyl,  
 5 3*H*-1,2,3-oxathiazolyl, 3*H*-1,2,4-oxathiazolyl, 3*H*-1,2,5-oxathiazolyl, 1,3,2-oxathiazolyl,  
 1,3,4-oxathiazolyl, 1,4,2-oxathiazolyl, 3*H*-1,2,4-dioxazolyl, 1,3,2-dioxazolyl,  
 1,4,2-dioxazolyl, 3*H*-1,2,3-dithiazolyl, 3*H*-1,2,4-dithiazolyl, 1,3,2-dithiazolyl,  
 1,4,2-dithiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,  
 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,  
 10 1*H*-1,2,3-triazolyl, 1*H*-1,2,4-triazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl,  
 1*H*-imidazolyl, 1*H*-pyrazolyl, 1*H*-pyrrolyl, furanyl, thienyl, 1*H*-pentazole; 6-membered  
 monocyclic rings such as 1,2,3-oxathiazinyl, 1,2,4-oxathiazinyl, 1,2,5-oxathiazinyl,  
 4*H*-1,3,5-oxathiazinyl, 1,4,2-oxathiazinyl, 1,4,3-oxathiazinyl, 1,2,3-dioxazinyl,  
 1,2,4-dioxazinyl, 4*H*-1,3,2-dioxazinyl, 4*H*-1,3,5-dioxazinyl, 1,4,2-dioxazinyl,  
 15 2*H*-1,5,2-dioxazinyl, 1,2,3-dithiazinyl, 1,2,4-dithiazinyl, 4*H*-1,3,2-dithiazinyl,  
 4*H*-1,3,5-dithiazinyl, 1,4,2-dithiazinyl, 2*H*-1,5,2-dithiazinyl, 2*H*-1,2,3-oxadiazinyl,  
 2*H*-1,2,4-oxadiazinyl, 2*H*-1,2,5-oxadiazinyl, 2*H*-1,2,6-oxadiazinyl, 2*H*-1,3,4-oxadiazinyl,  
 2*H*-1,3,5-oxadiazinyl, 2*H*-1,2,3-thiadiazinyl, 2*H*-1,2,4-thiadiazinyl, 2*H*-1,2,5-thiadiazinyl,  
 2*H*-1,2,6-thiadiazinyl, 2*H*-1,3,4-thiadiazinyl, 2*H*-1,3,5-thiadiazinyl, 1,2,3-triazinyl,  
 20 1,2,4-triazinyl, 1,3,5-triazinyl, 2*H*-1,2-oxazinyl, 2*H*-1,3-oxazinyl, 2*H*-1,4-oxazinyl,  
 2*H*-1,2-thiazinyl, 2*H*-1,3-thiazinyl, 2*H*-1,4-thiazinyl, pyrazinyl, pyridazinyl, pyrimidyl,  
 pyridyl, 2*H*-pyranyl, 2*H*-thiinyll; and to bicyclic rings such as 3*H*-1,2,3-benzoxathiazolyl,  
 1,3,2-benzodioxazolyl, 3*H*-1,2,3-benzodithiazolyl, 1,3,2-benzodithiazolyl, benzofurazanyl,  
 1,2,3-benzoxadiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzothiadiazolyl, 1*H*-benzotriazolyl,  
 25 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, benzoxazolyl, 1,2-benzisothiazolyl,  
 2,1-benzisothiazolyl, benzothiazolyl, 1*H*-benzimidazolyl, 1*H*-indazolyl,  
 3*H*-1,2-benzoxathiolyl, 1,3-benzoxathiolyl, 3*H*-2,1-benzoxathiolyl, 3*H*-1,2-benzodioxolyl,  
 1,3-benzodioxolyl 3*H*-1,2-benzodithiolyl, 1,3-benzodithiolyl, 1*H*-indolyl, 2*H*-isoindolyl,  
 benzofuranyl, isobenzofuranyl, 1-benzothienyl, 2-benzothienyl, 1*H*-2,1-benzoxazinyl,  
 30 1*H*-2,3-benzoxazinyl, 2*H*-1,2-benzoxazinyl, 2*H*-1,3-benzoxazinyl, , 2*H*-1,4-benzoxazinyl,  
 2*H*-3,1-benzoxazinyl, 1*H*-2,1-benzothiazinyl, 1*H*-2,3-benzothiazinyl,  
 2*H*-1,2-benzothiazinyl, 2*H*-1,3-benzothiazinyl, 2*H*-1,4-benzothiazinyl,  
 2*H*-3,1-benzothiazinyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, isoquinolyl,

quinolyl, 1*H*-2-benzopyranyl, 2*H*-1-benzopyranyl, 1*H*-2-benzothiopyranyl or 2*H*-1-benzothiopyranyl.

The acid addition salts of the compounds of the invention are pharmaceutically acceptable salts formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic and theophylline acetic acids, as well as the 8-halothephyllines, for example 8-bromothephylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.

The pharmaceutical compositions of this invention, or those which are manufactured in accordance with this invention, may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. For preparing such compositions, methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, excipients or other additives normally used in the art may be used.


Conveniently, the compounds of the invention are administered in unit dosage form containing said compounds in an amount of about 0.01 to 100 mg.

The total daily dose is usually in the range of about 0.05 - 500 mg, and most preferably about 0.1 to 50 mg of the active compound of the invention.


The compounds of the invention may be prepared as follows:

- 1) Alkylating a piperazine, piperidine or tetrahydropyridine of formula III with an alkylating derivative of formula II:

22



(II)




(III)


wherein  $R^1$ - $R^9$  and Q are as previously defined and L is a leaving group such as e.g. halogen, mesylate or tosylate;

5

2) Reductive alkylation of an amine of formula III with a reagent of formula IV:



(IV)



(III)


wherein  $R^1$ - $R^9$  and Q are as previously defined and E is an aldehyde or an activated carboxylic acid;

10

3) Acylating an amine of formula V by the use of a carboxylic acid and a coupling reagent, an activated ester, an acid chloride, an isocyanate, carbamoyl chloride or by a two-step procedure by treatment with phosgene followed by addition of an amine:

15

23



(V)

wherein R<sup>1</sup>-R<sup>9</sup> and Q are as previously defined, whereupon the compound of formula I is isolated as the free base or a pharmaceutically acceptable acid addition salt thereof.

5

The alkylation according to method 1) is conveniently performed in an organic solvent such as a suitably boiling alcohol or ketone, preferably in the presence of an organic or inorganic base (potassium carbonate, diisopropylethylamine or triethylamine) at reflux temperature. Alternatively, the alkylation can be performed at a fixed temperature, which is different from the boiling point, in one of the above-mentioned solvents or in dimethyl formamide (DMF), dimethylsulfoxide (DMSO), or N-methylpyrrolidin-2-one (NMP), preferably in the presence of a base. The alkylating agents of formula II can be prepared by methods analogous to those described in the examples or can be synthesised by applying methods described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc. New York, namely under reaction conditions such as those which are known and suitable for such reactions. The amines of formula III are either commercially available or have been described in the literature or can be prepared by methods analogous to those described in the literature e.g. Marxer et al. *J. Org. Chem.* **1975**, 40, 1427, by Parham et al. *J. Org. Chem.* **1976**, 41, 2628 and by Bauer et al. *J. Med. Chem.* **1976**, 19, 1315, Maligres et al. *Tetrahedron* **1997**, 53, 10983, and by Cheng et al. *Tet. Lett.* **1997**, 38, 1497, Chen, Meng-Hsin; Abraham, John A. *Tetrahedron Lett.* **1996**, 37, 5233-5234 and Slade, P.D. et al. *J. Med. Chem.* **1998**, 41, 1218-1235, or can be synthesised by methods described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John



Wiley & Sons, Inc. New York, namely under reaction conditions such as those which are known and suitable for such reactions.

The reductive alkylation according to method 2) is performed by standard literature methods or as described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc. New York, namely under reaction conditions such as those which are known and suitable for such reactions. The reaction can be performed in two steps, e.g. coupling of amines of formula III with a reagent of formula IV by standard methods *via* the carboxylic acid chloride, activated esters or by the use of carboxylic acids in combination with a coupling reagents such as e.g. dicyclohexyl carbodiimide, followed by reduction of the resulting amide with lithium aluminium hydride or alane. The carboxylic acids of formula IV are either commercially available or can be prepared by methods analogous to those described in the literature (e.g. *Tet. Lett.* 37, 1996, pp. 5453-5456; *Tet. Lett.* 35, 1994, pp. 6567-6570; *J. Med. Chem.* 25, 1982, pp. 1235-1240; *Synthesis* 1987, pp. 474-477).

The acylation according to method 3) is conveniently performed by standard methods *via* the carboxylic acid chloride, activated esters or by the use of carboxylic acids in combination with coupling reagents such as e.g. dicyclohexyl carbodiimide. When the acylating reagent is carbamoyl chlorides or isocyanates, the acylation produces urea derivatives. The urea derivatives can also be prepared by a two-step procedure consisting of treatment with phosgene followed by addition of an amine.

The intermediate compounds of formula V are prepared as described in methods 1) and 2), wherein  $R^2-R^9$ , Q, L and E are as previously defined, and  $R^1$  is a protection group. This protection group may be chosen from those protection group generally used for protection of amino groups. Those skilled in the art will know to select appropriate protection groups and how to protect and deprotect the amines with these protection groups.

## Experimental Section

Melting points were determined on a Büchi SMP-20 apparatus and are uncorrected. Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with

IonSpray source and Shimadzu LC-8A/SLC-10A LC system. The LC conditions (C18 column  $4.6 \times 30$  mm with a particle size of  $3.5 \mu\text{m}$ ) were linear gradient elution with water/acetonitrile/trifluoroacetic acid (90:10:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 4 min at 2 mL/min. Purity was determined by integration of the UV trace  
5 (254 nm). The retention times,  $R_t$ , are expressed in minutes.

Mass spectra were obtained by an alternating scan method to give molecular weight information. The molecular ion,  $\text{MH}^+$ , was obtained at low orifice voltage (5-20V) and fragmentation at high orifice voltage (100-200V).

10

Preparative LC-MS-separation was performed on the same instrument. The LC conditions (C18 column  $20 \times 50$  mm with a particle size of  $5 \mu\text{m}$ ) were linear gradient elution with water/acetonitrile/trifluoroacetic acid (80:20:0.05) to water/acetonitrile/trifluoroacetic acid (5:95:0.03) in 7 min at 22.7 mL/min. Fraction collection was performed by split-flow MS  
15 detection.

$^1\text{H}$  NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or at 250.13 MHz on a Bruker AC 250 instrument. Deuterated chloroform (99.8%D) or dimethyl sulfoxide (99.9%D) were used as solvents. TMS was used as internal reference  
20 standard. Chemical shift values are expressed in ppm-values. The following abbreviations are used for multiplicity of NMR signals: s=singlet, d=doublet, t=triplet, q=quartet, qui=quintet, h=heptet, dd=double doublet, dt=double triplet, dq=double quartet, tt=triplet of triplets, m=multiplet. NMR signals corresponding to acidic protons are generally omitted. For column chromatography silica gel of type Kieselgel 60, 230-400 mesh ASTM was used.  
25 For ion-exchange chromatography (SCX, 1 g, Varian Mega Bond Elut®, Chrompack cat. No. 220776) was used. Prior use of the SCX-columns was pre-conditioned with 10% solution of acetic acid in methanol (3 mL).

## Preparation of intermediates

### Alkylating reagents of the formula II

- 5 1. *(RS)*-1-(2-Bromo-ethyl)-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid-*tert*-butyl ester
- Tetrahydroisoquinolinic acid (10 g) was suspended in tetrahydrofuran THF (100 mL). Triethyl amine (9.1 mL) and di-*tert*-butyl dicarbonate (14.3 g) was added and the mixture stirred at room temperature for 16 h. The mixture was concentrated *in vacuo*, redissolved in ethyl acetate (250 mL) and washed twice with and aqueous 0.5 M KHSO<sub>4</sub>-solution (200
- 10 mL), dried over magnesium sulphate and evaporated *in vacuo* to give 1-carboxymethyl-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid *tert*-butyl ester in quantitative yield as a clear oil which crystallised upon standing. The protected amino acid was dissolved in dry tetrahydrofuran under nitrogen, cooled to 0 °C and 1M borane in tetrahydrofuran (41.5 mL) was added slowly under nitrogen during 15 min. The mixture was warmed to room
- 15 temperature and stirred for 1h. Excess borane was carefully destroyed by slow addition of 50 mL of a 1:1 mixture of water/tetrahydrofuran. The mixture was made alkaline to pH = 12 by addition of saturated potassium carbonate and extracted with diethylether (2 x 50 mL). The combined organic phase were dried (magnesium sulphate) and evaporated *in vacuo* to give 1-(2-Hydroxy-ethyl)-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid *tert*-butyl ester as
- 20 a clear oil (8.4 g). The protected aminoalcohol was dissolved in dry tetrahydrofuran (150 mL) together with triethylamine (5.6 mL) and cooled to 0 °C under nitrogen. Methanesulfonyl chloride (2.64 mL) in dry THF (30 mL) was added dropwise during 15 min and the mixture was warmed to room temperature and stirred for 30 min. After filtration and concentration *in vacuo* the clear oily residue was dissolved in acetone (300
- 25 mL), lithium bromide (14.6 g) was added and the mixture was heated to reflux for 1 h. The mixture was filtered, evaporated *in vacuo* and the product purified by column chromatography on silicagel using as eluent ethyl acetate/heptane (1:1) and fractions containing the product was pooled and evaporated *in vacuo* to give *(RS)*-1-(2-Bromo-ethyl)-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid-*tert*-butyl ester as a clear oil (8 g) which
- 30 crystallised upon standing.

The following compound was prepared in a similar way:

(RS)-1-(2-Bromo-ethyl)-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid-*tert*-butyl ester

### Piperidines of the formula III

5

The piperidine-derivatives of formula III, wherein X is oxygen, Z is CR<sup>9</sup>R<sup>10</sup>, Y is a bond, A<sup>1</sup>, A<sup>2</sup> and A<sup>4</sup> are CH, A<sup>3</sup> is CR<sup>11</sup>, i.e. spiro[isobenzofuran-1(3H),4'-piperidines] are prepared according to the methods described by Marxer et al. *J. Org. Chem.* **1975**, 40, 1427, by Parham et al. *J. Org. Chem.* **1976**, 41, 2628 and by Bauer et al. *J. Med. Chem.* **1976**, 19, 1315.

10

The following compounds were prepared in a similar way:

6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine],

6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine],

15 6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine],

6-trifluoromethyl-3-methylspiro[isobenzofuran-1(3H),4'-piperidine],

5-methylspiro[isobenzofuran-1(3H),4'-piperidine],

6-fluoro-3-isobutylspiro[isobenzofuran-1(3H),4'-piperidine],

6-fluoro-3-cyclohexylspiro[isobenzofuran-1(3H),4'-piperidine] and

20 6-fluoro-3-(4-fluorophenyl)spiro[isobenzofuran-1(3H),4'-piperidine]

The piperidine-derivatives of formula III, wherein X is CR<sup>9</sup>R<sup>10</sup>, Z is NR<sup>8</sup>, Y is a bond, A<sup>1</sup>, A<sup>2</sup> and A<sup>4</sup> are CH, A<sup>3</sup> is CR<sup>11</sup> and R<sup>11</sup> is fluoro or trifluoromethyl, are prepared according to the methods described by Maligres et al. *Tetrahedron* 1997, 53, 10983, and by Cheng et al.

25 *Tet. Lett.* 1997, 38, 1497.

The following compound was prepared in a similar way:

1-Acetyl-5-fluoro-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidine].

30 The piperidine-derivatives of formula III, wherein the X is CR<sup>9</sup>R<sup>10</sup>, Z is oxygen, Y is a bond, A<sup>1</sup>, A<sup>2</sup> and A<sup>4</sup> are CH, A<sup>3</sup> is CR<sup>11</sup>, i.e. 2,3-dihydro-spiro(benzofuran-3,4'-piperidines), are prepared according to the methods described by Chen, Meng-Hsin; Abraham, John A.

*Tetrahedron Lett.* **1996**, *37*, 5233-5234 and Slade, P.D. et al. *J. Med. Chem.* **1998**, *41*, 1218-1235.

The following compounds were prepared in a similar way:

- 5    2,3-Dihydro-5-fluorospiro[benzofuran-3,4'-piperidine] and  
     2,3-dihydro-5,6-difluorospiro[benzofuran-3,4'-piperidine]

The substituents R<sup>8</sup> -R<sup>11</sup> are introduced by applying suitably substituted starting compounds to methods analogous to the above mentioned.

10

#### Amines of the formula V

An amine of formula V was prepared by the following procedure:

- A mixture of an amine of formula III (1 mmol), (RS)-1-(2-Bromo-ethyl)-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid-*tert*-butyl ester (1.3 mmol) and potassium carbonate (1.3  
15    mmol) in acetonitrile (20 mL) were heated to 85 °C for 6 h. The mixture was cooled to room temperature and evaporated *in vacuo* to give an yellow oily residue. The product was redissolved in dichloromethane (10 mL) and anisole (0.26 mL) and trifluoroacetic acid (10 mL) were added and the mixture stirred at room temperature for 90 min. The mixture was evaporated *in vacuo*. The product was either purified by chromatography or used directly in  
20    the next step without purification.

The following compounds were purified by chromatography before further use:

- (RS)- 1-{2-[4-(5-Fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-1,2,3,4-tetrahydro-  
25    isoquinoline

(RS)-1-{2-[6-fluorospiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl}-  
1,2,3,4-tetrahydroisoquinoline

#### 30    Enantiomeric forms of Amines of the formula V

*Enantiomer 1 and enantiomer 2 of N-{4-(3-Fluoro-phenyl)-1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-piperidin-4-yl}acetamide*

Racemic N-{4-(3-fluoro-phenyl)-1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-piperidin-4-yl}acetamide was subjected to resolution by chiral HPLC using a Gilson SF3 supercritical fluid chromatography system equipped with chiralcelOD columns (4.6 mm x 25 cm for analytical and 10 mm x 25 cm for preparative runs). The particle size in the columns was 10  $\mu$ m. A solution of the racemic compound N-{4-(3-fluoro-phenyl)-1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-piperidin-4-yl}acetamide (1 g) in methanol (1 mL) was injected in 40  $\mu$ L portions on a preparative column. The column was eluted with carbondioxide – modifier (75:25). The modifier was 2-propanol with diethylamine (0.5%) and trifluoroacetic acid (0.5%). The flow was 18.9 mL/min at 20 Mpa. Fraction collection was triggered by UV-detection (210 nm). The fractions containing the separate products were pooled and evaporated *in vacuo* which gave the enantiomers. The first eluted enantiomer is called Enantiomer 1 and the second eluted is called Enantiomer 2 of N-{4-(3-fluoro-phenyl)-1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-piperidin-4-yl}acetamide. The enantiomers were measured by HPLC to have an enantiomeric excess higher than 95%.

The following enantiomers were prepared in a similar way:

*Enantiomer 1 and enantiomer 2 of N-{4-(phenyl)-1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-piperidin-4-yl}acetamide*

## Examples

### Preparation of the compounds of the invention

The compounds of the present invention were prepared by one of two general methods:

#### **Method A: Alkylating a piperidine of formula III with an alkylating derivative of formula II:**

A mixture of a piperidine of formula III (1 mmol), (RS)-1-(2-Bromo-ethyl)-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid-*tert*-butyl ester (1.3 mmol) and potassium carbonate (1.3 mmol) in acetonitrile (20 mL) were heated to 85 °C for 6 h. The mixture was cooled to room temperature and evaporated *in vacuo*. The product was purified by chromatography either on silicagel using as eluent ethylacetate/triethylamine (99:1) or by purified by HPLC. Fractions containing the product were pooled and evaporated *in vacuo*.

**Method B: Acylating an amine of formula V by the use of a carboxylic acid and a coupling reagent, an activated ester, an acid chloride or an isocyanate:**

An amine of formula V (prepared as described above; 1 mmol) and triethylamine (5 mmol) were dissolved in anhydrous acetonitrile (10 mL). An appropriately substituted acid chloride (5 mmol) was added and the reaction mixture stirred at room temperature for 30 min. Methanol (0.5 mL) was added to the reaction mixture followed by evaporation *in vacuo*. The product was purified by chromatography either on silicagel using ethylacetate/triethylamine (99:1) as eluent or by HPLC. Fractions containing the product were pooled and evaporated *in vacuo* and characterised by HPLC-UV-ELSD-MS. The measured HPLC-retention time, the measured molecular mass and UV- and ELSD-purities are shown in **table 1**.

**The following compounds were made by the methods indicated in table 1. Analytical data are shown in table 1.**

**Compound**

1. 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
2. 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
3. 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid phenethyl-amide
4. 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-phenylmethanone
5. 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(2-fluoro-phenyl)methanone
6. 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-3-phenyl-propan-1-one
7. 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid (3-chloro-propyl)amide
8. 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid (2-methoxy-phenyl)amide

9. 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid tert-butyl ester
10. 3-Chloro-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-2,2-dimethyl-propan-1-one
- 5 12. 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
13. 1-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
14. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-  
10 *1H*-isoquinoline-2-carboxylic acid tert-butyl ester
15. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-phenylmethanone
16. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-p-tolylmethanone
- 15 17. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(2-methoxy-phenyl)methanone
18. 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
19. 1-(2-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone  
20
20. 1-(2-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
21. 1-(4-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 25 22. 1-(4-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
23. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid phenethyl amide
24. 1-(1-{2-[6-Fuorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-  
30 *1H*-isoquinolin-2-yl)-1-(4-methoxy-phenyl)methanone
25. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-3-phenyl-propan-1-one



26. 2-Ethyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)-butan-1-one
27. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(3-methoxy-phenyl)methanone
- 5 28. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)-2-phenylethanone
29. 3-Cyclohexyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)-propan-1-one
30. 2-(4-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)ethanone
- 10 31. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid (3,4-dichloro-phenyl)amide
32. 1-Cyclopropyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 15 33. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-pyridin-3-yl-methanone
34. 1-[5-(4-Chloro-phenyl)-2-methyl-furan-3-yl]-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
35. 2-(4-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)ethanone
- 20 36. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)-2-methyl-propan-1-one
37. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid (2-ethyl-phenyl)amide
- 25 38. *N*-[1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluorophenyl)-piperidin-4-yl]acetamide
39. 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidin-1'-yl]]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
40. 1-Cycloheptyl-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone
- 30 41. *N*-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-phenylpiperidin-4-yl)acetamide

42. 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl})methanone
43. 1-(4-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
- 5 44. 1-Cycloheptyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
45. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-1-piperidin-1-ylmethanone
46. 1-(4-Fluorophenyl)-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-1*H*-indol-10 3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
47. 1-Cycloheptyl-1-(1-{2-[4-(2-methyl-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
48. 1-Cycloheptyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
- 15 49. 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl})methanone
50. 1-Cyclopentyl-1-{1-[spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
51. 1-Cyclopentyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-1*H*-indol-20 3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
52. 1-(4-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl})methanone
53. 1-(2-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
- 25 54. 1-Cycloheptyl-1-(1-{2-[spiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone
55. 1-Cycloheptyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl})methanone
56. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-30 1-cycloheptylmethanone
57. 1-Cyclopentyl-1-(1-{2-[5-isopropylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl})methanone

58. N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide
59. 1-Cycloheptyl-1-{1-[2-(4-phenylpiperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 5 60. 1-Cycloheptyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
61. 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
62. 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
- 10 63. 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
64. 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone
- 15 65. 1-[1-(2-{2-[1-(4-Fluorophenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenylpiperidin-4-yl]-1-piperidin-1-yl-methanone
66. 1-Cyclopentyl-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
67. 8-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one
- 20 68. 1-Cycloheptyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
69. 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]-1-(4-methyl-piperazin-1-yl)methanone
- 25 70. 1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidine-4-carboxylic acid ethyl ester
71. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-ethanone
72. 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
- 30 73. 1-Cyclopentyl-1-(1-{2-[4-(2-methyl-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone

74. 1-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)ethanone
75. 1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 5 76. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
77. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)-1-(4-fluoro-phenyl)methanone
78. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-1-(4-methyl-piperazin-1-yl)methanone
- 10 79. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-cyclopentylmethanone
80. 1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 15 81. 1-(4-Fluorophenyl)-1-(1-{2-[piro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
82. 1-Cyclopentyl-1-(1-{2-[4-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
83. 1-(2-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 20 84. N-[4-(3-Fluoro-phenyl)-1-(2-{2-[1-(4-fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl)-piperidin-4-yl]-acetamide
85. 1-(2-Fluorophenyl)-1-{1-[spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 25 86. 1-Cycloheptyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
87. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-1-piperidin-1-ylmethanone
88. 1-{1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}-1-cycloheptylmethanone
- 30 89. 1-(2-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone

90. 1-(1-{2-[(Chloro-trifluoromethyl-phenyl)-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-cycloheptylmethanone
91. 1-(1-{2-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-cycloheptylmethanone
- 5 92. 1-Cycloheptyl-1-(1-{2-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
93. 1-(1-{2-[4-(7-Chloro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-cyclopentylmethanone
94. 1-Cyclopentyl-1-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 10 3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
95. 1-(1-{2-[4-(2,3-Dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
96. N-[1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide
- 15 97. 1-(4-Fluoro-phenyl)-1-{1-[2-(4-phenyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
98. 1-(1-{2-[4-(6-Chloro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
99. 1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 20 100. 1-Cycloheptyl-1-{1-[spirop[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
101. N-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide
- 25 102. 1-(1-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(2-fluoro-phenyl)methanone
103. 1-cycloheptyl-1-(1-{2-[spirop[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
104. 1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidine-4-carboxylic acid ethyl ester
- 30 105. 1-(1-{2-[4-(4-Dimethylamino-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone

- 106.1-Cyclopentyl-1-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 107.1-[1-(2-{2-[1-(4-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]ethanone
- 5 108.1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]ethanone
- 109.1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]-1-piperidin-1-yl-methanone
- 110.1-Cyclopentyl-1-{1-[2-(4-phenyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 10 111.1-(2-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 112.1-(4-Fluoro-phenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- 15 113.1-(4-Fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
114. 3,3-Dimethyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-butan-1-one
115. Cyclohexyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-methanone
- 20 116. Cyclohexyl-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
117. Cyclohexyl-[1-{2-[spiro(benzofuran-3*H*-1,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-methanone
- 25 118. Cyclohexyl-(1-{2-[4-(2-methyl-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
119. N-{1-[2-(2-Cyclohexanecarbonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-4-phenyl-piperidin-4-yl}-acetamide
120. 3,3-Dimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-butan-1-one
- 30 121. Cyclohexyl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone

122. Cyclohexyl-(1-{2-[4-(4-dimethylamino-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
123. 3-Phenyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-propanone
- 5 124. (1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-cyclohexyl-methanone
125. 2-Phenoxy-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-ethan-1-one
126. Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- 10 127. Cyclohexyl-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
128. 2-Propyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-pentan-1-one
- 15 129. 2,2-Dimethyl-3-chlor-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-propan-1-one
130. Cyclohexyl-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
131. 3,3-Dimethyl-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-butan-1-one
- 20 132. Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
133. 2-Ethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-butan-1-one
- 25 134. 2-Benzyloxy-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-ethan-1-one
135. Benzo[1,2,5]oxadiazol-5-yl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-methanone
136. (1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-cyclohexyl-methanone
- 30 137. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one

138. 3,5,5-Trimethyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-  
3,4-dihydro-1H-isoquinoline-2-yl]-hexan-1-one
139. 3,5,5-Trimethyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-  
1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-hexan-1-one
- 5 140. 2-Phenoxy-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl}-  
3,4-dihydro-1H-isoquinolin-2-yl)-ethan-1-one
141. (1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-  
(2,2-dichloro-cyclopropyl)-methanone
142. 2-Benzyloxy-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-  
10 3,4-dihydro-1H-isoquinoline-2-yl]-ethan-1-one
143. 1-(1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-  
6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one
144. 1-(1-{2-[4-(2,3-Dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-  
1H-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one
- 15 145. 3,5,5-Trimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-  
3,4-dihydro-1H-isoquinolin-2-yl)-hexan-1-one
146. 2,2-Dimethyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-  
3,4--dihydro-1H-isoquinoline-2-yl]-propan-1-one
147. 3-Cyclohexyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-  
20 3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
148. Furan-2-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-  
3,4-dihydro-1H-isoquinoline-2-yl]-methanone
149. N-(4-Phenyl-1-{2-[2-(3,5,5-trimethyl-hexanoyl)-1,2,3,4-tetrahydro-isoquinolin-  
1-yl]-ethyl}-piperidin-4-yl)-acetamide
- 25 150. Quinoxalin-2-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-  
3,4-dihydro-1H-isoquinoline-2-yl]-methanone
151. 3-Cyclohexyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-  
3,4-dihydro-1H-isoquinoline-2-yl]-propan-1-one
152. Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-  
ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 30 153. Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-  
ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone



154. (Tetrahydro-pyran-4-yl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
155. 2-Propyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-pentan-1-one
- 5 156. 2-Ethyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-butan-1-one
157. 3-Phenyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
158. 3,3-Dimethyl-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-butan-1-one
- 10 159. (1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-(2,2-dichloro-cyclopropyl)-methanone
160. 1,2,3,4-tetrahydro-naphthalene-2-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 15 161. (4-Methylsulfanyl-phenyl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
162. 3,5,5-Trimethyl-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-hexan-1-one
163. 3-Phenyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
- 20 164. Furan-2-yl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
165. 2-Benzyloxy-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone
- 25 166. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-2-phenoxy-ethanone
167. Quinoxalin-2-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
168. 2,2-Dimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
- 30 169. (2,2-Dichloro-cyclopropyl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone

170. 4-Methylsulfanyl-phenyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
171. (2,2-Dichloro-cyclopropyl)-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 5 172. 1-(1-{2-[4-(4-Isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-3,5,5-trimethyl-hexan-1-one
173. 2,2-Dichloro-cyclopropyl-(1-{2-[spiro(isobenzofuran-3H-1,4'-piperidine-1'-yl)]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
174. N-(4-Phenyl-1-{2-[2-(1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)-acetamide
- 10 175. Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(4-chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
176. N-(1-{2-[2-(3,3-Dimethyl-butyryl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-acetamide
- 15 177. 3-Chloro-2,2-dimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
178. Tetrahydro-pyran-4-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)]-ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-butan-1-one

20 **The following compounds were made as enantiomers by method B starting from Enantiomer 2 of the corresponding amines of formula V. Analytical data are shown in table 1.**

#### **Compound**

- 25 179. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(2-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
180. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(2-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
181. N-[1-{2-[2-(4-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- 30 182. N-[1-{2-[2-(4-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)

183. N-[1-{2-[2-(4-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
184. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-isopropyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- 5 185. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-methyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
186. N-[1-{2-[2-(3-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
187. N-[1-{2-[2-(2-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- 10 188. N-(1-{2-[2-(4-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
189. N-(1-{2-[2-(2,4-Dichloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- 15 190. N-[1-{2-[2-(2,4-Dichloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
191. N-[1-{2-[2-(Benzo[1,2,5]oxadiazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
192. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- 20 193. N-[1-[2-(2-Cyclopentanecarbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
194. N-(1-{2-[2-(4-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- 25 195. N-[1-{2-[2-(Benzo[b]thiophene-3-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
196. N-[1-{2-[2-(6-Fluoro-4H-benzo[1,3]dioxine-8-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]acetamide (Enantiomer)
197. N-[1-{2-[2-(3-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]acetamide (Enantiomer)
- 30 198. N-[1-{2-[2-(2-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]acetamide (Enantiomer)

199. N-(1-{2-[2-(4-Methyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
200. N-[1-{2-[2-(2-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- 5 201. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
202. N-(1-{2-[2-(3-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
203. N-(1-{2-[2-(4-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-  
10 piperidin-4-yl)acetamide (Enantiomer)
204. N-{1-[2-(2-Cycloheptanecarbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl}-acetamide (Enantiomer)
205. N-(1-{2-[2-(3-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- 15 206. 2-N-(4-(3-Fluoro-phenyl)-1-{2-[2-(3-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
207. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(thiophene-3-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
208. N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-pyrazol-1-yl-benzoyl)-1,2,3,4-tetrahydro-  
20 isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
209. N-(1-{2-[2-(Naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)

25 **Table 1.** Measured molecular mass ( $M+H^+$ ), measured HPLC-retention time (RT, min) and UV- and ELSD-purities (%) and synthesis method.

compound	$M+H^+$	RT min.	UV-purity (%)	ELSD-purity (%)	Synthesis method
1	500.3	2.34	84.41	100	B
2	474.4	2.38	83.5	100	B
3	496.3	2.45	75.89	100	B
4	481.9	2.29	83.81	100	B

5	500.2	2.29	83.54	100	B
6	510	2.46	84.14	100	B
7	497.4	2.29	100	100	B
8	525.4	2.40	89.67	100	B
9	478.2	2.20	75.37	99.26	A
10	497.1	2.36	75.37	99.26	B
12	463	2.31	100	100	B
13	598.1	2.45	93.85	100	B
14	467	2.43	73.81	96.61	B
15	471.2	2.21	93.09	100	B
16	485	2.34	86.3	100	B
17	501.2	2.27	94.08	100	B
18	491.1	2.54	100	100	B
19	488.9	2.22	84.77	100	B
20	504.9	2.27	77.86	100	B
21	489.2	2.25	80.99	100	B
22	505.1	2.39	85.64	100	B
23	514.2	2.42	79.04	100	B
24	501.3	2.25	83.93	99.53	B
25	499.1	2.42	91.88	100	B
26	465.1	2.34	97.12	100	B
27	501.1	2.25	82.81	100	B
28	485.2	2.27	72.97	100	B
29	505.2	2.73	71.89	100	B
30	502.8	2.31	74.17	100	B
31	554.2	2.60	95.47	100	B
32	435.2	2.06	86.69	100	B
33	472	1.80	95.32	100	B
34	585	2.81	96.53	100	B
35	519	2.44	89.59	100	B
36	437.3	2.13	91.14	100	B
37	514.2	2.40	85.04	100	B
38	520.3	2.29	71.77	76.11	B

39	477.4	2.43	91.78	100	B
40	514.3	2.33	91.25	99.32	B
41	502.3	2.35	70.93	83.59	B
42	551.3	2.44	90.64	100	B
43	503.1	2.37	74.38	100	B
44	550.1	2.50	73.67	95.11	B
45	528.3	2.44	93.37	79.93	B
46	548.2	2.22	94.88	100	B
47	498.3	2.66	74.25	96.35	B
48	513.3	2.77	100	97.34	B
49	537.1	2.33	89.23	100	B
50	486.4	2.12	99.47	100	B
51	522.3	2.29	100	100	B
52	563.1	2.27	72.61	100	B
53	489.2	2.23	76.61	100	B
54	473.6	2.51	70.49	82.63	B
55	565.3	2.55	72.19	100	B
56	479.2	2.74	74.67	83.39	B
57	487.3	2.66	82.69	99.27	B
58	492.2	2.08	85.05	100	B
59	445.5	2.58	70.23	73.14	B
60	505.2	2.65	71.04	76.63	B
61	485.1	2.57	88.72	100	B
62	523.4	2.23	100	100	B
63	549.3	2.19	93.44	100	B
64	502.4	2.29	91.44	100	B
65	554.3	2.38	93.61	100	B
66	435.3	2.38	72.75	93.86	B
67	515.3	2.51	77.67	78.14	B
68	601.3	2.63	81.38	97.64	B
69	569.3	1.65	76.77	88.30	B
70	517.3	2.67	79.03	86.76	B
71	487.4	2.50	72.35	95.17	B

72	573.5	2.42	90.45	100	B
73	470.4	2.45	83.20	100	B
74	459.4	2.27	92.31	100	B
75	599.3	2.36	96.26	98.55	B
76	477.2	2.40	100	93.03	B
77	491.3	2.51	86.66	73.72	B
78	631.5	1.84	75.78	100	B
79	451.1	2.50	86.14	100	B
80	511.1	2.48	100	100	B
81	471.3	2.23	92.66	100	B
82	463.3	2.36	100	100	B
83	563.1	2.24	90.29	100	B
84	518.2	2.03	95.48	100	B
85	512.2	2.02	94.94	88.11	B
86	610.5	2.41	94.60	98.31	B
87	616.2	2.56	89.81	100	B
88	459.3	2.69	71.44	73.94	B
89	599.2	2.33	91.53	100	B
90	623.4	2.65	87.37	98.35	B
91	555.3	2.44	89.31	100	B
92	503.2	2.90	71.70	70.84	B
93	490.2	2.48	100	100	B
94	459.2	2.42	83.29	100	B
95	485.3	2.33	94.29	100	B
96	580.5	2.22	96.44	100	B
97	443.2	2.25	98.80	100	B
98	516	2.42	90.05	100	B
99	461.2	2.29	100	100	B
100	574.4	2.26	99.42	100	B
101	474.4	2.02	100	100	B
102	502.3	2.23	94.60	100	B
103	533.1	2.41	87.36	97.35	B
104	489.4	2.46	79.39	100	B

105	486.4	1.65	88.94	100	B
106	459.5	2.74	81.14	100	B
107	485.4	2.21	94.86	100	B
108	485	2.16	70.08	70.13	B
109	554.4	2.34	70.00	74.91	B
110	417.2	2.35	92.41	100	B
111	549.4	2.14	95.35	100	B
112	507,5	2,45	88.27	98.43	B
113	489.6	2.33	89.20	97.90	B
114	464,6	2,39	97,56	100	B
115	476,6	2,44	97,18	100	B
116	472,7	2,53	98,22	100	B
117	458,6	2,40	86,63	100	B
118	483,7	2,53	99,38	100	B
119	487,7	2,13	95,52	100	B
120	486,6	2,62	94,23	100	B
121	498,6	2,66	98,51	100	B
122	473,7	1,75	94,26	100	B
123	498,6	2,44	97,66	100	A
124	609,1	2,54	97,77	100	B
125	500,6	2,32	93,9	98,82	B
126	508,6	2,37	98,82	100	B
127	472,7	2,83	95,08	100	B
128	492,7	2,63	97,33	100	B
129	485	2,29	94,23	99,4	B
130	472,7	2,52	95,96	100	B
131	460,7	2,49	96,36	100	B
132	534,6	2,48	94,21	99,15	B
133	486,6	2,58	86,65	100	B
134	510,7	2,41	75,55	96,08	B
135	512,6	2,29	98,04	100	B
136	465,1	2,58	96,36	100	B
137	453,1	2,54	97,52	100	B



138	506,7	2,78	98,11	100	B
139	502,7	2,88	77,28	94,4	B
140	496,6	2,39	97,44	100	B
141	491,9	2,44	99,44	99,2	B
142	514,6	2,34	91,48	98,85	B
143	597,1	2,49	97,94	100	B
144	460,7	2,49	95,22	100	B
145	528,7	2,98	98,91	100	B
146	450,6	2,28	100	100	B
147	526,7	2,92	96,57	99,25	B
148	460,5	2,10	96,13	99,34	B
149	517,8	2,50	99,13	100	B
150	522,6	2,26	92,92	99,26	B
151	504,7	2,73	97,79	100	B
152	508,6	2,33	99,37	100	B
153	519,6	2,33	99,06	100	B
154	500,6	2,19	96	99,4	B
155	514,7	2,85	93,87	100	B
156	464,6	2,36	91,14	100	B
157	520,6	2,64	94,34	99,05	B
158	471,7	2,51	97,9	100	B
159	635,9	2,39	96,68	98,58	B
160	520,7	2,69	92,98	99,42	B
161	538,7	2,62	97,24	98,81	B
162	513,8	2,88	95,64	100	B
163	494,7	2,52	98,25	100	B
164	482,5	2,32	91,14	100	B
165	521,7	2,41	93,78	100	B
166	489,1	2,45	97,97	100	B
167	518,7	2,34	87,58	97,31	B
168	472,6	2,50	94,41	99,01	B
169	525,4	2,52	98,4	98,78	B
170	512,7	2,50	98,1	99,2	B

171	499,5	2,37	98,66	99,01	B
172	502,8	3,15	96,92	100	B
173	485,5	2,28	86,08	99,43	B
174	535,7	2,32	89,96	99,01	B
175	501	2,42	98,67	100	B
176	475,7	2,09	97,47	100	B
177	507	2,52	90,73	100	B
178	478,6	1,94	91,92	100	B
179	530,3	2,01	89.59	99.31	B
180	550,2	2,32	96.42	98.14	B
181	534,2	2,15	99.1	100	B
182	578,2	2,18	99.05	100	B
183	518,2	2,00	98.42	99.38	B
184	542,4	2,34	93.23	99.9	B
185	514,4	2,09	99.41	100	B
186	534,2	2,11	98.69	100	B
187	578,3	2,04	71.31	100	B
188	562,2	2,13	95.59	100	A
189	550,2	2,22	88.21	95.21	B
190	568,4	2,22	86.21	98.71	B
191	542,4	2,03	99.09	100	B
192	550,2	2,17	97.37	100	B
193	492,3	2,07	81.75	100	B
194	516,3	2,09	96.4	100	B
195	556,3	2,15	99.36	99.89	B
196	576,3	2,03	96.774	100	B
197	580,4	2,14	98.59	100	B
198	518,2	1,95	82.81	99.74	B
199	496,2	2,15	91.36	99.03	B
200	534,2	2,01	79.14	99.08	B
201	530,3	2,01	99.08	100	B
202	516,3	2,16	94.57	98.33	B
203	500,5	1,97	96.4	100	B

<b>204</b>	502,4	2,25	88.94	100	B
<b>205</b>	562,1	2,20	93.75	96.46	B
<b>206</b>	530,3	2,00	98.7	100	B
<b>207</b>	506,2	1,92	98.2	100	B
<b>208</b>	566,4	1,99	98.45	100	B
<b>209</b>	532,2	2,21	93.74	98.44	B

### Pharmacological Testing

- 5 The compounds of the invention were tested in a well-recognised and reliable test. The test was as follows:

#### Inhibition of binding of $^{125}\text{I}$ -NKA to human NK2 receptors

- 10 The compounds of the invention have been found to potently inhibit the binding of  $^{125}\text{I}$ -NKA to the human NK2 receptor.

By this method, the inhibition by drugs of the binding of  $^{125}\text{I}$ -NKA to membranes of human cloned NK2 receptors expressed in CHO-cells is determined *in vitro*.

15

- Briefly, the affinity of the compounds was measured by their ability to displace  $^{125}\text{I}$ -NKA, by incubating hNK2 expressing CHO membranes with compound and radioligand at room temperature for 60 minutes. Incubation was terminated by rapid filtration through GF/C filters, and filters were counted in a Wallac Trilux Scintillation Counter. The IC<sub>50</sub> values for the compounds No. 1-209, exemplified above, was determined to be 200 nM or less. For the majority of the compounds the IC<sub>50</sub> values were 50 nM or less, and for a large group of the compounds the IC<sub>50</sub> values were 10 nM or less.
- 20

### Formulation Examples

25

The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.

For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine. Examples of adjuvants or diluents comprise: Corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.

Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to the desired volume, sterilising the solution and filling it in suitable ampoules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.

Typical examples of recipes for the formulation of the invention are as follows:

- 1) Tablets containing 5.0 mg of a compound of the invention calculated as the free base:

Compound <b>1a</b> or <b>1b</b>	5.0 mg
Lactose	60 mg
Maize starch	30 mg
Hydroxypropylcellulose	2.4 mg
Microcrystalline cellulose	19.2 mg
Croscarmellose Sodium Type A	2.4 mg
Magnesium stearate	0.84 mg


- 2) Tablets containing 0.5 mg of a compound of the invention calculated as the free base:

Compound <b>1a</b> or <b>1b</b>	0.5 mg
Lactose	46.9 mg
Maize starch	23.5 mg
Povidone	1.8 mg
Microcrystalline cellulose	14.4 mg
Croscarmellose Sodium Type A	1.8 mg
Magnesium stearate	0.63 mg

3)		Syrup containing per millilitre:	
	Compound <b>1a</b> or <b>1b</b>	25 mg	
	Sorbitol	500 mg	
5	Hydroxypropylcellulose	15 mg	
	Glycerol	50 mg	
	Methyl-paraben	1 mg	
	Propyl-paraben	0.1 mg	
	Ethanol	0.005 mL	
10	Flavour	0.05 mg	
	Saccharin sodium	0.5 mg	
	Water	ad 1 mL	
15	4)	Solution for injection containing per millilitre:	
	Compound <b>1a</b> or <b>1b</b>	0.5 mg	
	Sorbitol	5.1 mg	
	Acetic Acid	0.05 mg	
	Saccharin sodium	0.5 mg	
20	Water	ad 1 mL	

## Patent Claims

1. A 3,4-dihydro-1H-isoquinoloin-2-yl-derivative of formula I



wherein

$R^1$  is a group  $R^{11}CO-$ ,  $R^{11}CS-$ ,  $R^{11}SO_2-$ ,  $R^{11}OCO-$ ,  $R^{11}SCO-$  or  $R^{11}CO-CR^{12}R^{13}-$  wherein  
 10  $R^{11}$  is  $C_{1-12}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, aryl, aryl- $C_{1-6}$ -alkyl, heteroaryl, heteroaryl- $C_{1-6}$ -alkyl, tetrahydropyranyl, 1,2,3,4-tetrahydronaphtalenyl, or 4H-benzo[1,3]dioxinyl optionally substituted with halogen wherein each of said  $C_{1-6}$ -alkyl, aryl, heteroaryl and  $C_{3-8}$ -cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group  
 15 comprising halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy, aryl- $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylsulfanyl, aryl and aryloxy wherein said aryl and aryloxy independently are unsubstituted or substituted with one or more halogen, and  $R^{12}$  and  $R^{13}$  independently are hydrogen or  $C_{1-6}$ -alkyl; or  $R^1$  is a group  $R^{14}R^{15}NCO-$ ,  $R^{14}R^{15}NCS-$ , wherein  $R^{14}$  and  $R^{15}$  are independently hydrogen,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, aryl or  
 20 aryl- $C_{1-6}$ -alkyl, wherein each of said  $C_{1-6}$ -alkyl, aryl and  $C_{3-8}$ -cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen,  $C_{1-6}$ -alkyl and  $C_{1-6}$ -alkoxy, or  $R^{14}$  and  $R^{15}$  together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group;

25

$R^2$  is selected from hydrogen, trifluoromethyl and  $C_{1-6}$ -alkyl;

$R^3$ - $R^6$ ,  $R^{7a}$ ,  $R^{7b}$ ,  $R^{8a}$  and  $R^{8b}$  are independently selected from hydrogen, halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, amino,  $C_{1-6}$ -alkylamino, di- $(C_{1-6}$ -alkyl)amino,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di- $(C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and  $C_{1-6}$ -alkylsulfonyl;


m is 2-6;

$R^9$  is benzyl, benzoyl, 2,3-dihydrobenzofuranyl or mono- or bicyclic aryl or heteroaryl wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, amino,  $C_{1-6}$ -alkylamino, di- $(C_{1-6}$ -alkyl)amino,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di- $(C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl;

Q is C, N or  $CR^{10}$ ;

wherein  $R^{10}$  is selected from hydrogen, halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, amino,  $C_{1-6}$ -alkylamino, di- $(C_{1-6}$ -alkyl)amino,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di- $(C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl, a group  $-NR^{30}COR^{31}$  wherein  $R^{30}$  is hydrogen or  $C_{1-6}$ -alkyl and  $R^{31}$  is  $C_{1-6}$ -alkyl, a group  $-COOR^{16}$  wherein  $R^{16}$  is hydrogen or  $C_{1-6}$ -alkyl, or a group  $-CONR^{17}R^{18}$  wherein  $R^{17}$  and  $R^{18}$  independently are selected from hydrogen and  $C_{1-6}$ -alkyl or  $R^{17}$  and  $R^{18}$  together with the nitrogen to which they are attached form a piperidiny, piperaziny or morpholinyl, wherein said piperidiny, piperaziny and morpholinyl is unsubstituted or substituted with a  $C_{1-6}$ -alkyl;

or  $R^9$  and  $R^{10}$  together with the carbon to which they are attached form a cyclic structure selected from the group comprising:



5 wherein Q' is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure; and

X, Y, and Z are independently chosen from O; NR<sup>19</sup>; CR<sup>23</sup>R<sup>24</sup>; S(O)<sub>n</sub> and a bond; wherein R<sup>19</sup> is selected from hydrogen, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or R<sup>19</sup> is a group R<sup>20</sup>SO<sub>2</sub>-, R<sup>20</sup>OCO- or R<sup>20</sup>SCO- wherein R<sup>20</sup> is C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl or aryl, or R<sup>19</sup> is a group R<sup>21</sup>R<sup>22</sup>NCO- or R<sup>21</sup>R<sup>22</sup>NCS-, wherein R<sup>21</sup> and R<sup>22</sup> are independently hydrogen, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, or aryl, wherein said

15 aryl is unsubstituted or substituted with one or more substituents selected from C<sub>1-6</sub>-alkyl or halogen; or R<sup>21</sup> and R<sup>22</sup> together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group; R<sup>23</sup> and R<sup>24</sup> are independently selected from hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted

20 with one or more substituents selected from C<sub>1-6</sub>-alkyl or halogen, amino, C<sub>1-6</sub>-alkylamino, a group NR<sup>25</sup>R<sup>26</sup> wherein R<sup>25</sup> and R<sup>26</sup> are independently selected from C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and C<sub>1-6</sub>-alkylsulfonyl or R<sup>25</sup> and R<sup>26</sup> together with the N-atom to which they are linked, form a

25 pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, or R<sup>23</sup> and R<sup>24</sup> together is




oxo; and n is 0, 1 or 2; provided that no more than one of X, Y and Z may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time be selected from O and S; and

- 5  $A^1$ ,  $A^2$ ,  $A^3$  and  $A^4$  are independently selected from N and  $CR^{27}$  wherein  $R^{27}$  is hydrogen, halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di-  
( $C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl  $C_{1-6}$ -alkylsulfonyl amino or a group  
10  $NR^{28}R^{29}$  wherein  $R^{28}$  and  $R^{29}$  are independently selected from hydrogen and  $C_{1-6}$ -alkyl or  $R^{28}$  and  $R^{29}$  together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group; provided that only one of  $A^1$ ,  $A^2$ ,  $A^3$  and  $A^4$  may be N; and

- 15 the dotted line emanating from Q is a bond when Q is C, and no bond when Q is  $CR^{10}$  or N;

or a pharmaceutically acceptable acid addition salt thereof.

2. A compound according to claim 1 characterised in that Q is  $CR^{10}$ , and  $R^9$  and  $R^{10}$   
20 together with the carbon to which they are attached form a bicyclic structure:



1),

wherein Q' is the carbon shared with the piperidine ring, so that said bicyclic structure together with said piperidine ring form a spiro structure; and

25

- X, Y and Z are independently chosen from O;  $NR^{19}$ ;  $CR^{23}R^{24}$  and  $S(O)_n$  wherein  $R^{19}$  is selected from hydrogen,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or  $R^{19}$  is a group  $R^{20}SO_2-$ ,  $R^{20}OCO-$  or  $R^{20}SCO-$  wherein  $R^{20}$  is  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  
30  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, or aryl, or  $R^{19}$  is a group


$R^{21}R^{22}NCO-$ ,  $R^{21}R^{22}NCS-$ , wherein  $R^{21}$  and  $R^{22}$  are independently hydrogen,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, or aryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from  $C_{1-6}$ -alkyl or halogen; or  $R^{21}$  and  $R^{22}$  together with the N-atom to which they are linked, form a  
 5 pyrrolidiny, piperidiny, or perhydroazepiny group;  $R^{23}$  and  $R^{24}$  are independently selected from hydrogen, halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from  $C_{1-6}$ -alkyl or halogen, amino,  $C_{1-6}$ -alkylamino, a group  $NR^{25}R^{26}$  wherein  $R^{25}$  and  $R^{26}$  are independently selected from  $C_{1-6}$ -alkyl or  $R^{25}$  and  
 10  $R^{26}$  together with the N-atom to which they are linked, form a pyrrolidiny, piperidiny, perhydroazepiny, or morpholiny group,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di- $(C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and  $C_{1-6}$ -alkylsulfonyl or  $R^{23}$  and  $R^{24}$  together is oxo; and n is 0, 1 or 2; and a bond; provided that no more than one of X, Y and Z  
 15 may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time be selected from O and S; and

$A^1$ ,  $A^2$ ,  $A^3$  and  $A^4$  are independently selected from N and  $CR^{27}$  wherein  $R^{27}$  is hydrogen, halogen, cyano, nitro,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl,  $C_{3-8}$ -cycloalkyl,  $C_{3-8}$ -cycloalkyl- $C_{1-6}$ -alkyl, amino, a group  $NR^{28}R^{29}$  wherein  $R^{28}$  and  $R^{29}$  are independently selected from  
 20 hydrogen and  $C_{1-6}$ -alkyl or  $R^{28}$  and  $R^{29}$  together with the N-atom to which they are linked, form a pyrrolidiny, piperidiny, perhydroazepiny or morpholiny group,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di- $(C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl  
 25 or  $C_{1-6}$ -alkylsulfonyl; provided that only one of  $A^1$ ,  $A^2$ ,  $A^3$  and  $A^4$  may be N.

3. A compound according to claim 2 characterised in that X, Y and Z are selected from one of the combinations: X is oxygen, Y is a bond and Z is  $CR^{23}R^{24}$ ; X is  $CR^{23}R^{24}$ , Y is a bond and Z is oxygen; X is  $NR^{19}$ , Y is a bond and Z is  $CR^{23}R^{24}$ ; X is  $CR^{23}R^{24}$ , Y is a bond  
 30 and Z is  $NR^{19}$ ; X is CO, Y is a bond and Z is  $NR^{19}$ ; X is SO<sub>2</sub>, Y is a bond and Z is  $NR^{19}$ ; X is SO, Y is a bond and Z is  $NR^{19}$ ; X is  $CR^{23}R^{24}$ , Y is a bond and Z is S; X is  $CR^{23}R^{24}$ , Y is a bond and Z is SO; X is  $CR^{23}R^{24}$ , Y is a bond and Z is SO<sub>2</sub>; wherein  $R^{19}$  is hydrogen, acetyl


or methylsulfonyl and  $R^{23}$  and  $R^{24}$  are independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl.

4. A compound according to claim 2 characterised in that -X-Y-Z- together form a group selected from:  $-O-CR^{23}R^{24}-$ ,  $-CR^{23}R^{24}-O-$ ,  $-NR^{19}-CR^{23}R^{24}-$ ,  $-CR^{23}R^{24}-NR^{19}-$ ,  $-CO-NR^{19}-$ ,  $-SO_2-NR^{19}-$ ,  $-SO-NR^{19}-$ ,  $-CR^{23}R^{24}-S-$ ,  $-CR^{23}R^{24}-SO-$ ,  $-CR^{23}R^{24}-SO_2-$ ; wherein  $R^{19}$  is hydrogen, acetyl or methylsulfonyl and  $R^{23}$  and  $R^{24}$  are independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl.
5. A compound according to any of claims 2 to 4 characterised in that  $A^3$  is N or  $CR^{27}$  wherein  $R^{27}$  is halogen, cyano, nitro, a group  $NR^{28}R^{29}$  wherein  $R^{28}$  and  $R^{29}$  are independently selected from hydrogen and  $C_{1-6}$ -alkyl or  $R^{28}$  and  $R^{29}$  together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group,  $C_{1-6}$ -alkylcarbonyl, aminocarbonyl,  $C_{1-6}$ -alkylaminocarbonyl, di- $(C_{1-6}$ -alkyl)aminocarbonyl,  $C_{1-6}$ -alkoxy, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl, or  $C_{1-6}$ -alkylsulfonyl.
6. A compound according to any of claims 2 to 5 characterised in that  $A^1$ ,  $A^2$ ,  $A^3$  and  $A^4$  are independently selected from  $CR^{27}$  wherein  $R^{27}$  is as defined above.
7. A compound according to claim 2 characterised in that said bicyclic structure is selected from the group comprising:




wherein  $R^{19'}$  is acetyl or methylsulfonyl,  $R^{23'}$  is hydrogen or methyl,  $R^{27'}$  is hydrogen or fluoro,  $R^{27''}$  is hydrogen, fluoro, methyl or isopropyl,  $R^{27'''}$  is hydrogen, fluoro or trifluoromethyl.


8. A compound according to claim 1 characterised in that R<sup>9</sup> and R<sup>10</sup> together with the carbon to which they are attached form a cyclic structure selected from the group comprising:



2)



3)



4)

5

wherein Q' is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure.

9. A compound according to claim 1 characterised in that R<sup>9</sup> is benzyl, benzoyl, 2,3-dihydrobenzofuran-7-yl or mono- or bicyclic aryl or heteroaryl wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino, C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl)amino, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.

10. A compound according to claim 9 characterised in that R<sup>9</sup> is 2,3-dihydrobenzofuran-7-yl, benzyl or benzoyl wherein said benzyl or benzoyl is unsubstituted or substituted with one or more halogens in the phenyl groups, or R<sup>9</sup> is mono- or bicyclic aryl or heteroaryl selected from the group comprising phenyl, indolyl, pyridyl, thiophenyl and benzisoxazolyl, wherein each aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino, C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl)amino, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.

11. A compound according to claim 10 characterised in that said mono- or bicyclic aryl or heteroaryl is selected from the group comprising phenyl, indol-3-yl and benzisoxazol-3-yl wherein said phenyl, indol-3-yl or benzisoxazol-3-yl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, amino, C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl)amino, C<sub>1-6</sub>-alkylcarbonyl, aminocarbonyl, C<sub>1-6</sub>-alkylaminocarbonyl, di-(C<sub>1-6</sub>-alkyl)aminocarbonyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.
12. A compound according to claim 11 characterised in that said optional substituents are selected from the group comprising halogen, phenyl and methyl.
13. A compound according to any of claims 9 to 12 characterised in that Q is CR<sup>10</sup> wherein R<sup>10</sup> is selected from hydrogen, C<sub>1-6</sub>-alkylcarbonyl, hydroxy, a group -NR<sup>30</sup>COR<sup>31</sup> wherein R<sup>30</sup> is hydrogen or C<sub>1-6</sub>-alkyl and R<sup>31</sup> is C<sub>1-6</sub>-alkyl, a group -COOR<sup>16</sup> wherein R<sup>16</sup> is C<sub>1-6</sub>-alkyl, or a group -CONR<sup>17</sup>R<sup>18</sup> wherein R<sup>17</sup> and R<sup>18</sup> together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl, wherein said piperidinyl, piperazinyl and morpholinyl is unsubstituted or substituted with a C<sub>1-6</sub>-alkyl.
14. A compound according to claim 13 characterised in that R<sup>10</sup> is selected from hydrogen, acetyl, hydroxy, a group -NR<sup>30</sup>COR<sup>31</sup> wherein R<sup>30</sup> is hydrogen and R<sup>31</sup> is methyl, a group -COOR<sup>16</sup> wherein R<sup>16</sup> is ethyl, or a group -CONR<sup>17</sup>R<sup>18</sup> wherein R<sup>17</sup> and R<sup>18</sup> together with the nitrogen to which they are attached form a piperidinyl or a 4-methylpiperazinyl.
15. A compound according to any of claims 1 to 14 characterised in that m is 2,3 or 4.
16. A compound according to claim 15 characterised in that m is 2.
17. A compound according to any of claims 1 to 16 characterised in that R<sup>1</sup> is a group R<sup>11</sup>CO-, R<sup>11</sup>OCO- wherein R<sup>11</sup> is C<sub>3-6</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, phenyl, phenyl-C<sub>1-6</sub>-alkyl, pyridyl, furanyl, benzo[1,2,5]oxadiazolyl, quinoxalinyl, benzo[b]thiophenyl or naphthalenyl wherein each of said C<sub>3-6</sub>-alkyl, phenyl, pyridyl and

furanyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy, phenyl and phenoxy wherein said phenyl and phenoxy independently are unsubstituted or substituted with one halogen; or R<sup>1</sup> is a group R<sup>14</sup>R<sup>15</sup>NCO-, wherein R<sup>14</sup> and R<sup>15</sup> are independently hydrogen, C<sub>1-6</sub>-alkyl, aryl, or aryl-C<sub>1-6</sub>-alkyl, wherein each of said C<sub>1-6</sub>-alkyl and aryl groups  
5 independently are unsubstituted or substituted with one substituent selected from the group comprising halogen and C<sub>1-6</sub>-alkoxy.

10 18. A compound according to any of claims 1 to 17 characterised in that R<sup>2</sup> is hydrogen.

19. A compound according to any of claims 1 to 18 characterised in that R<sup>3</sup> is hydrogen.

20. A compound according to any of claims 1 to 19 characterised in that R<sup>4</sup> is hydrogen or methoxy.

15 21. A compound according to any of claims 1 to 20 characterised in that R<sup>5</sup> is hydrogen or methoxy.

22. A compound according to any of claims 1 to 21 characterised in that R<sup>6</sup> is hydrogen.

20 23. A compound according to any of claims 1 to 22 characterised in that R<sup>7a</sup> and R<sup>7b</sup> is hydrogen.

25 24. A compound according to any of claims 1 to 23 characterised in that R<sup>8a</sup> and R<sup>8b</sup> is hydrogen.

25. A compound according to claim 1 characterised in that it is selected from the group comprising:

1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-  
30 2-yl)-1-(4-fluoro-phenyl)methanone  
1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-  
*1H*-isoquinolin-2-yl)methanone

- 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid phenethyl-amide
- 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-phenylmethanone
- 5 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(2-fluoro-phenyl)methanone
- 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-3-phenyl-propan-1-one
- 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid (3-chloro-propyl)amide
- 10 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid (2-methoxy-phenyl)amide
- 1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid tert-butyl ester
- 15 3-Chloro-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-2,2-dimethyl-propan-1-one
- 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 1-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 20 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid tert-butyl ester
- 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-phenylmethanone
- 25 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-p-tolylmethanone
- 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(2-methoxy-phenyl)methanone
- 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 30 1-(2-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone

- 1-(2-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-(4-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 5 1-(4-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid phenethyl amide
- 1-(1-{2-[6-Fuorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-10 1*H*-isoquinolin-2-yl)-1-(4-methoxy-phenyl)methanone
- 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-3-phenyl-propan-1-one
- 2-Ethyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-butan-1-one
- 15 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(3-methoxy-phenyl)methanone
- 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-2-phenylethanone
- 3-Cyclohexyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-propan-1-one
- 20 3,4-dihydro-1*H*-isoquinolin-2-yl)-propan-1-one
- 2-(4-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)ethanone
- 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid (3,4-dichloro-phenyl)amide
- 25 1-Cyclopropyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-pyridin-3-yl-methanone
- 1-[5-(4-Chloro-phenyl)-2-methyl-furan-3-yl]-1-(1-{2-[6-fluorospiro[isobenzofuran-30 1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 2-(4-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)ethanone



- 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)-2-methyl-propan-1-one
- 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinoline-2-carboxylic acid (2-ethyl-phenyl)amide
- 5 *N*-[1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide
- 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidin-1'-yl]]-ethyl}-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 1-Cycloheptyl-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone
- 10 *N*-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl)acetamide
- 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-*1H*-isoquinolin-2-yl)methanone
- 15 1-(4-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 1-Cycloheptyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl)-1-piperidin-1-ylmethanone
- 20 1-(4-Fluorophenyl)-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 1-Cycloheptyl-1-(1-{2-[4-(2-methyl-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 25 1-Cycloheptyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone
- 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-*1H*-isoquinolin-2-yl)methanone
- 1-Cyclopentyl-1-{1-[spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl}methanone
- 30 1-Cyclopentyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone

- 1-(4-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 1-(2-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 5 1-Cycloheptyl-1-(1-{2-[spiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-Cycloheptyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-
- 10 1-cycloheptylmethanone
- 1-Cyclopentyl-1-(1-{2-[5-isopropylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluorophenyl)-piperidin-4-yl]acetamide
- 15 1-Cycloheptyl-1-{1-[2-(4-phenylpiperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 1-Cycloheptyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)piperidin-1-yl]-ethyl]-3,4-dihydro-
- 20 1*H*-isoquinolin-2-yl)methanone
- 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 25 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone
- 1-[1-(2-{2-[1-(4-Fluorophenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl)-4-phenylpiperidin-4-yl]-1-piperidin-1-yl-methanone
- 1-Cyclopentyl-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl]-ethyl]-3,4-dihydro-
- 30 1*H*-isoquinolin-2-yl)methanone
- 8-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one

- 1-Cycloheptyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]-1-(4-methyl-piperazin-1-yl)methanone
- 5 1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidine-4-carboxylic acid ethyl ester
- 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-ethanone
- 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 10 1-Cyclopentyl-1-(1-{2-[4-(2-methyl-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)ethanone
- 15 1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone
- 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
- 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)-1-(4-fluoro-phenyl)methanone
- 20 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-1-(4-methyl-piperazin-1-yl)methanone
- 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-cyclopentylmethanone
- 25 1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-(4-Fluorophenyl)-1-(1-{2-[piro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-Cyclopentyl-1-(1-{2-[4-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 30 1-(2-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl)methanone

- N-[4-(3-Fluoro-phenyl)-1-(2-{2-[1-(4-fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-piperidin-4-yl]-acetamide
- 1-(2-Fluorophenyl)-1-{1-[spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 5 1-Cycloheptyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
- 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-1-piperidin-1-ylmethanone
- 1-{1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}-
- 10 1-cycloheptylmethanone
- 1-(2-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
- 1-(1-{2-[(Chloro-trifluoromethyl-phenyl)-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-cycloheptylmethanone
- 15 1-(1-{2-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-cycloheptylmethanone
- 1-Cycloheptyl-1-(1-{2-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-(1-{2-[4-(7-Chloro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-
- 20 2-yl)-1-cyclopentylmethanone
- 1-Cyclopentyl-1-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 1-(1-{2-[4-(2,3-Dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
- 25 N-[1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide
- 1-(4-Fluoro-phenyl)-1-{1-[2-(4-phenyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 1-(1-{2-[4-(6-Chloro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-
- 30 1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
- 1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone

- 1-Cycloheptyl-1-{1-[spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
- N-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide
- 5 1-(1-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(2-fluoro-phenyl)methanone
- 1-cycloheptyl-1-(1-{2-[spiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
- 1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-
- 10 piperidine-4-carboxylic acid ethyl ester
- 1-(1-{2-[4-(4-Dimethylamino-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
- 1-Cyclopentyl-1-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone
- 15 1-[1-(2-{2-[1-(4-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]ethanone
- 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]ethanone
- 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]-1-piperidin-1-yl-methanone
- 20 1-Cyclopentyl-1-{1-[2-(4-phenyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 1-(2-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-6,7-dimethoxy-1*H*-isoquinolin-2-yl}methanone
- 25 1-(4-Fluoro-phenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone
- 3,3-Dimethyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-butan-1-one
- 30 Cyclohexyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-methanone

- Cyclohexyl-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- Cyclohexyl-[1-{2-[spiro(benzofuran-3*H*-1,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-methanone
- 5 Cyclohexyl-(1-{2-[4-(2-methyl-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- N-{1-[2-(2-Cyclohexanecarbonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-4-phenyl-piperidin-4-yl}-acetamide
- 3,3-Dimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-10 1*H*-isoquinolin-2-yl)-butan-1-one
- Cyclohexyl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- Cyclohexyl-(1-{2-[4-(4-dimethylamino-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- 15 3-Phenyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-propanone
- (1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-cyclohexyl-methanone
- 2-Phenoxy-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-20 1*H*-isoquinoline-2-yl]-ethan-1-one
- Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- Cyclohexyl-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- 25 2-Propyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-pentan-1-one
- 2,2-Dimethyl-3-chlor-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-propan-1-one
- Cyclohexyl-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-30 1*H*-isoquinolin-2-yl)-methanone
- 3,3-Dimethyl-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-butan-1-one

- Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone
- 2-Ethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-butan-1-one
- 5 2-Benzyloxy-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-ethan-1-one
- Benzo[1,2,5]oxadiazol-5-yl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-methanone
- (1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-cyclohexyl-methanone
- 10 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one
- 3,5,5-Trimethyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-hexan-1-one
- 15 3,5,5-Trimethyl-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-hexan-1-one
- 2-Phenoxy-(1-{2-[spiro(5-methyl-isobenzofuran-3*H*-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-ethan-1-one
- (1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-(2,2-dichloro-cyclopropyl)-methanone
- 20 2-Benzyloxy-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-ethan-1-one
- 1-(1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one
- 25 1-(1-{2-[4-(2,3-Dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one
- 3,5,5-Trimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-hexan-1-one
- 2,2-Dimethyl-[1-{2-[spiro(5-fluor-benzofuran-2*H*-3,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1*H*-isoquinoline-2-yl]-propan-1-one
- 30 3-Cyclohexyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1*H*-isoquinolin-2-yl)-propan-1-one

- Furan-2-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-methanone
- N-(4-Phenyl-1-{2-[2-(3,5,5-trimethyl-hexanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)-acetamide
- 5 Quinoxalin-2-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-methanone
- 3-Cyclohexyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-propan-1-one
- Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 10 Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- (Tetrahydro-pyran-4-yl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 15 2-Propyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-pentan-1-one
- 2-Ethyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-butan-1-one
- 3-Phenyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
- 20 3,3-Dimethyl-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-butan-1-one
- (1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-(2,2-dichloro-cyclopropyl)-methanone
- 25 1,2,3,4-tetrahydro-naphthalene-2-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- (4-Methylsulfanyl-phenyl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 3,5,5-Trimethyl-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-hexan-1-one
- 30 3-Phenyl-1-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one



- Furan-2-yl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 2-Benzoyloxy-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone
- 5 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-2-phenoxy-ethanone
- Quinoxalin-2-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 2,2-Dimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
- 10 (2,2-Dichloro-cyclopropyl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 4-Methylsulfanyl-phenyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 15 (2,2-Dichloro-cyclopropyl)-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 1-(1-{2-[4-(4-Isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-3,5,5-trimethyl-hexan-1-one
- 2,2-Dichloro-cyclopropyl-(1-{2-[spiro(isobenzofuran-3H-1,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 20 3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- N-(4-Phenyl-1-{2-[2-(1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)-acetamide
- Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(4-chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone
- 25 N-(1-{2-[2-(3,3-Dimethyl-butyryl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-acetamide
- 3-Chloro-2,2-dimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
- Tetrahydro-pyran-4-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)]ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-butan-1-one
- 30 1-(1-{2-[4-(5-Fluoro-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,

- 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-Chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 5 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 10 1'-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- N*-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- 15 *N*-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl} methanone,
- 20 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl} methanone,
- 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro *1H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl} methanone,
- 25 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl} methanone,
- 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-(4-Fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 30 3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,

- 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,
- 1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-methanone,
- 5 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)-methanone,
- 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5-chloro-3,4-dihydro-*1H*-isoquinolin-2-yl)methanone,
- 10 1-(1-{2-[4-(5-Fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-*1H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,
- 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-*1H*-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-*1H*-isoquinolin-2-yl)methanone,
- 15 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-*1H*-isoquinolin-2-yl)methanone,
- 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-*1H*-isoquinolin-2-yl)methanone,
- 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-*1H*-isoquinolin-2-yl)methanone,
- 20 1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]ethyl}-3,4-dihydro-5-fluoro-*1H*-isoquinolin-2-yl)methanone,
- N*-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- 25 *N*-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- N*-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- 30 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-*1H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-5-fluoro-*1H*-isoquinolin-2-yl}methanone,

- 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl}methanone,  
1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro 1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl}methanone,
- 5 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl}methanone,  
1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,
- 10 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,  
1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,
- 15 1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,  
1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)-methanone,
- 20 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-3,4-dihydro-5-fluoro-1*H*-isoquinolin-2-yl)methanone,  
1-(1-{2-[4-(5-Fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,
- 25 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 30 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,


- 1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
- 5 N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,  
N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- 10 N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,  
1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,  
1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,
- 15 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro 1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,  
1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,  
1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 20 1-(4-Fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,
- 25 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 30 1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl]-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone,

- 1-Cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(1-{2-[4-(5-Fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,
- 5 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-1*H*-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 10 5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,
- 15 *N*-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,  
*N*-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yl]acetamide,  
*N*-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,
- 20 4-phenylpiperidin-4-yl]acetamide,  
*N*-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenylpiperidin-4-yl]acetamide,  
1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,
- 25 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,  
1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro 1*H*-indol-3,4'-piperidin-1'-yl]-ethyl]-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,  
1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,
- 30 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-1*H*-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl}methanone,  
1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,

- 1-(4-Fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-  
5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-  
1*H*-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,  
5 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-  
1*H*-isoquinolin-2-yl)-1-(cyclopentyl)methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl}-  
5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone,  
1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl}-  
10 5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone,  
1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl}-  
5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-methanone, and  
1-Cyclopentyl-1-(1-{2-[6-fluorospiro[benzofuran-1(3*H*),4'-piperidine-1'-yl]-ethyl}-  
5,6-difluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)methanone.

15

or from the group comprising the following enantiomers which are prepared by acylation of  
Enantiomer 2 of the corresponding amines of formula V,



- 20 wherein R<sup>2</sup>-R<sup>9</sup> and Q are as defined for formula I;

and Enantiomer 2 is the slowly eluting of the enantiomer pair by supercritical HPLC at  
20 Mpa on a system comprising chiralcelOD columns and an eluent consisting of  
carbondioxide(75%), 2-propanol(24.75%), diethylamine(0.125%) and trifluoroacetic  
25 acid(0.125%):

- N-(4-(3-Fluoro-phenyl)-1-{2-[2-(2-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- N-(4-(3-Fluoro-phenyl)-1-{2-[2-(2-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- 5 N-[1-{2-[2-(4-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- N-[1-{2-[2-(4-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- N-[1-{2-[2-(4-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- 10 N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-isopropyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-methyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- 15 N-[1-{2-[2-(3-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- N-[1-{2-[2-(2-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- N-(1-{2-[2-(4-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- 20 N-(1-{2-[2-(2,4-Dichloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- N-[1-{2-[2-(2,4-Dichloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- 25 N-[1-{2-[2-(Benzo[1,2,5]oxadiazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- N-(4-(3-Fluoro-phenyl)-1-{2-[2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- N-[1-[2-(2-Cyclopentanecarbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl]-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- 30 N-(1-{2-[2-(4-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)



- N-[1-{2-[2-(Benzo[b]thiophene-3-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- N-[1-{2-[2-(6-Fluoro-4H-benzo[1,3]dioxine-8-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]acetamide (Enantiomer)
- 5 N-[1-{2-[2-(3-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]acetamide (Enantiomer)
- N-[1-{2-[2-(2-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]acetamide (Enantiomer)
- N-(1-{2-[2-(4-Methyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-  
10 piperidin-4-yl)acetamide (Enantiomer)
- N-[1-{2-[2-(2-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer)
- N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- 15 N-(1-{2-[2-(3-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- N-(1-{2-[2-(4-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- N-{1-[2-(2-Cycloheptanecarbonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-4-phenyl-  
20 piperidin-4-yl}-acetamide (Enantiomer)
- N-(1-{2-[2-(3-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- 2-N-(4-(3-Fluoro-phenyl)-1-{2-[2-(3-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- 25 N-(4-(3-Fluoro-phenyl)-1-{2-[2-(thiophene-3-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-pyrazol-1-yl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)
- N-(1-{2-[2-(Naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-  
30 piperidin-4-yl)acetamide (Enantiomer)

**26.** A pharmaceutical composition comprising a compound of any of claims 1 to 25 in a therapeutically effective amount together with one or more pharmaceutically acceptable carriers or diluents.

5 **27.** Use of a compound of any of claims 1 to 25 for the manufacture of a pharmaceutical preparation for the treatment of a disorder in the central nervous system.

**28.** Use according to claim 27 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety  
10 depression, generalized anxiety disorder, social anxiety disorder, panic anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis and Huntington's disease as well as Parkinson's dementia, adjustment disorders, pain, emesis, migraine, epilepsy, obesity and cerebrovascular disease.

15

**29.** Use according to claim 28 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalized anxiety disorder, social anxiety disorder, panic anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia,  
20 pre-menstrual dysphoric disorder and psychosis.

**30.** Use of a compound of any of claims 1 to 25 in treatment of a disorder in the central nervous system.

25 **31.** Use according to claim 30 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis and Huntington's disease as well as  
30 Parkinson's dementia, adjustment disorders, pain, emesis, migraine, epilepsy, obesity and cerebrovascular disease.

32. Use according to claim 31 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalized anxiety disorder, social anxiety disorder, panic anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, 5 pre-menstrual dysphoric disorder and psychosis.

1  
INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 02/00858

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 409/12, C07D 471/04, C07D 489/04, A61K 31/445, A61K 31/44  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN-CAPLUS, MEDLINE, EMBASE, EPODOC, BEILSTEIN, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9717344 A1 (ASTRA AKTIEBOLAG), 15 May 1997 (15.05.97), claims 1-26 --	1-31
A	US 6465483 B1 (WALTER LÖSEL ET AL), 15 October 2002 (15.10.02), claims 1-15 --	1-31
A	US 3994891 A (JOHN LAWRENCE HUGHES ET AL), 30 November 1976 (30.11.76), claims 1-13 --	1-31
A	DE 4104257 A1 (BOEHRINGER INGELHEIM KG), 20 August 1992 (20.08.92), claims 1-29 --	1-31

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 March 2003

Date of mailing of the international search report

25-03-2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Fernando Farieta/Els

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 02/00858

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 3827727 A1 (BOEHRINGER INGELHEIM KG), 22 February 1990 (22.02.90), claims 1-29  -- -----	1-31

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

30/12/02

International application No.  
PCT/DK 02/00858

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
WO	9717344	A1	15/05/97	AT 213241 T	15/02/02
				AU 701329 B	28/01/99
				AU 4960896 A	23/09/96
				AU 7592796 A	29/05/97
				BR 9611276 A	26/01/99
				CZ 9801392 A	16/09/98
				DE 69619259 D,T	19/09/02
				DK 861250 T	29/04/02
				EE 9800141 A	15/10/98
				EP 0820226 A	28/01/98
				EP 0861250 A,B	02/09/98
				SE 0861250 T3	
				ES 2171743 T	16/09/02
				HU 9900142 A	28/05/99
				IL 124296 D	00/00/00
				JP 2000500132 T	11/01/00
				NO 982072 A	03/07/98
				NZ 322227 A	29/11/99
				PL 326554 A	28/09/98
				PT 861250 T	31/07/02
				SE 9600275 D	00/00/00
				SI 861250 T	00/00/00
				SK 61098 A	11/01/99
				TR 9800813 T	00/00/00
				TW 458978 B	00/00/00
				US 6140322 A	31/10/00
				SE 9603300 D	00/00/00
				SE 9603301 D	00/00/00
				ZA 9609091 A	07/05/97
-----					

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

30/12/02

International application No.  
PCT/DK 02/00858

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	6465483	B1	15/10/02	AT	197706 T	15/12/00
				AU	688833 B	19/03/98
				AU	1314295 A	10/07/95
				CA	2178088 A	29/06/95
				CN	1138324 A	18/12/96
				DE	4343641 A	29/06/95
				DE	59409595 D	00/00/00
				DK	736012 T	29/01/01
				EP	0736012 A,B	09/10/96
				SE	0736012 T3	
				ES	2152379 T	01/02/01
				GR	3035108 T	30/03/01
				IL	112102 D	00/00/00
				JP	9506880 T	08/07/97
				PL	315052 A	30/09/96
				PT	736012 T	30/03/01
				SI	736012 T	00/00/00
				US	5607943 A	04/03/97
				US	5837712 A	17/11/98
				US	5925650 A	20/07/99
				US	6180645 B	30/01/01
				WO	9517388 A	29/06/95
				ZA	9410116 A	21/06/95
				DE	4343684 A	22/06/95
-----						
US	3994891	A	30/11/76	NONE		
-----						
DE	4104257	A1	20/08/92	AU	1199092 A	15/09/92
				IE	920451 A	12/08/92
				IL	100927 D	00/00/00
				WO	9214465 A	03/09/92
				ZA	9201039 A	30/09/92
-----						
DE	3827727	A1	22/02/90	AU	637767 B	10/06/93
				AU	3992589 A	22/02/90
				DD	285595 A	19/12/90
				DD	295379 A	31/10/91
				DD	297640 A	16/01/92
				DE	8817109 U	26/11/92
				DK	399789 A	17/02/90
				EP	0358957 A	21/03/90
				FI	893832 A	17/02/90
				FI	921541 A	08/04/92
				HU	51277 A	28/04/90
				HU	208434 B	28/10/93
				IL	91301 D	00/00/00
				JP	2160767 A	20/06/90
				MX	9203260 A	01/07/92
				NO	893270 A	19/02/90
				PH	27356 A	22/06/93
				PL	161521 B	30/07/93
				PT	91451 A	08/03/90
				ZA	8906205 A	24/04/91
-----						

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/DK02/00858**

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **30-31**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see next sheet**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



**INTERNATIONAL SEARCH REPORT**

International application No.  
**PCT/DK02/00858**

Claims 30-31 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/ Rule. 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.